Page last updated: 2024-10-19

niacin and Hyperlipemia

niacin has been researched along with Hyperlipemia in 299 studies

Niacin: A water-soluble vitamin of the B complex occurring in various animal and plant tissues. It is required by the body for the formation of coenzymes NAD and NADP. It has PELLAGRA-curative, vasodilating, and antilipemic properties.
vitamin B3 : Any member of a group of vitamers that belong to the chemical structural class called pyridines that exhibit biological activity against vitamin B3 deficiency. Vitamin B3 deficiency causes a condition known as pellagra whose symptoms include depression, dermatitis and diarrhea. The vitamers include nicotinic acid and nicotinamide (and their ionized and salt forms).
nicotinic acid : A pyridinemonocarboxylic acid that is pyridine in which the hydrogen at position 3 is replaced by a carboxy group.

Research Excerpts

ExcerptRelevanceReference
"To assess the efficacy and safety of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in hyperlipidaemic patients with diabetes mellitus (DM), metabolic syndrome (MetS) without DM (MetS/non-DM) or neither (non-DM/non-MetS)."9.14Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. ( Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE, 2010)
"To assess the lipid-lowering effects and safety of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia."9.08A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. ( Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S, 1998)
"To review the pathophysiology and clinical relevance for using niacin to treat the metabolic syndrome."8.82The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. ( Ito, MK, 2004)
"Two 65-year-old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment."7.70Dental and gingival pain as side effects of niacin therapy. ( Davis, WJ; Gordon, NF; Leighton, RF; Small, GS; Ward, ES, 1998)
"Postprandial (non-fasting) hyperlipemia is characterized by increased blood levels of exogenous triglycerides (TG) in the form of apolipoprotein (apo) B48-containing TG-rich lipoproteins (TRL), which have a causal role in the pathogenesis and progression of cardiovascular disease (CVD)."6.53Pharmacological Effects of Niacin on Acute Hyperlipemia. ( Abia, R; Bermudez, B; la Paz, SM; Lopez, S; Muriana, FJ; Naranjo, MC, 2016)
"Niacin is considered to be a powerful drug for the treatment of lipid and lipoprotein abnormalities connected with "residual cardiovascular risk", which persist in high-risk patients even when the target goals of LDL-C are achieved with statin therapy."6.52Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place? ( Hromádka, R; Perlík, F; Staňková, B; Tvrzická, E; Vecka, M; Žák, A; Zeman, M, 2015)
"Bezafibrate was effective hypolipidemic agent in normal rats, but addition of nicotinic acid has certainly improved the effectiveness further which could be of clinical significance."5.28Effect of bezafibrate & nicotinic acid on triton induced hyperlipidemias in CFY rats. ( Krishnamurthy, A; Thapar, GS, 1991)
"To compare the effects of combination niacin extended-release + simvastatin (NER/S) versus atorvastatin alone on apolipoproteins and lipid fractions in a post hoc analysis from SUPREME, a study which compared the lipid effects of niacin extended-release + simvastatin and atorvastatin in patients with hyperlipidemia or mixed dyslipidemia."5.14Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy. ( Insull, W; Jiang, P; Krause, S; Padley, RJ; Parreno, RA; Superko, HR; Thakkar, RB; Toth, PP, 2010)
"To assess the efficacy and safety of ezetimibe/simvastatin (E/S) plus extended-release niacin (N) in hyperlipidaemic patients with diabetes mellitus (DM), metabolic syndrome (MetS) without DM (MetS/non-DM) or neither (non-DM/non-MetS)."5.14Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome. ( Fazio, S; Guyton, JR; Lin, J; Shah, A; Tershakovec, AM; Tomassini, JE, 2010)
"To evaluate the efficacy and safety of extended-release niacin (niacin ER) either alone or in combination with atorvastatin for the lipid profile modification in the patients with coronary heart disease (CHD) and its equivalents."5.12[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification]. ( Duan, J; Li, XP; Tan, MY; Xu, ZM; Zhang, DQ; Zhao, SP, 2006)
"To assess the lipid-lowering effects and safety of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia."5.08A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group. ( Black, DM; Kafonek, S; Koren, M; McCormick, LS; McKenney, JM; Weiss, S, 1998)
"It appears from this pilot study that preceding niacin with 325 mg of aspirin will decrease the warmth and flushing associated with niacin."5.07The effect of aspirin on niacin-induced cutaneous reactions. ( Fowler, SF; Hainer, BL; Price, SO; Whelan, AM, 1992)
"To minimize the cutaneous flushing symptoms associated with niacin use, a time-release capsule form of niacin has been formulated."5.05Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin. ( Albers, JJ; Burrows, E; Ginsberg, J; Hoff, C; Knopp, RH; Ogilvie, JT; Poole, M; Retzlaff, B; Warnick, GR, 1985)
" In this article, we briefly review the clinical trial data on the efficacy, safety and influence on non-lipid atherosclerosis factors of combined therapy statin with fibrates, statin with nicotinic acid and statin with ezetimibe."4.84[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors]. ( Balcerak, M; Broncel, M; Chojnowska-Jezierska, J, 2007)
" Dyslipidemia in patients with nonalcoholic fatty liver disease or nonalcoholic steatohepatitis may improve with use of statins, fibrates, niacin, and thiazolidinediones, but the data are presently very limited."4.82Management of dyslipidemia in patients with complicated metabolic syndrome. ( Davidson, MH, 2005)
"To review the pathophysiology and clinical relevance for using niacin to treat the metabolic syndrome."4.82The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin. ( Ito, MK, 2004)
" Recently, it has been shown that some of the most prescribed fibrates cause hyperhomocysteinemia, which itself has been recognised as a cardiovascular risk factor."4.82The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels. ( Dierkes, J; Luley, C; Westphal, S, 2004)
" Many of these patients, as well as persons at heightened risk for cardiovascular disease because of a range of heritable conditions (eg, familial hypercholesterolemia, familial combined hyperlipidemia), will undoubtedly require binary or ternary regimens involving statins in concert with niacin, fibric-acid derivatives, or bile acid resins."4.81Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century. ( Jacobson, TA, 2001)
"This study determined time trends between 2007 and 2011 for statin and nonstatin lipid-lowering therapy (niacin, fibrates, bile acid sequestrants, and ezetimibe) use among Medicare beneficiaries with coronary heart disease (CHD) in light of emerging clinical trial evidence."3.81Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011. ( Bittner, V; Deng, L; Farkouh, ME; Glasser, SP; Kent, ST; Muntner, P; Rosenson, RS; Taylor, B, 2015)
"In the field of dyslipidemia and metabolic syndrome, four innovative therapies are reviewed: Ezetimibe (Ezétrol) is a selective cholesterol absorption inhibitor."3.73[Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)]. ( Ducobu, J, 2005)
"Two 65-year-old white men with coronary heart disease, given niacin therapy for dyslipidemia for 5 months, developed intense dental and gingival pain that was associated with increases in dose and that was relieved with discontinuance of niacin treatment."3.70Dental and gingival pain as side effects of niacin therapy. ( Davis, WJ; Gordon, NF; Leighton, RF; Small, GS; Ward, ES, 1998)
"High-dose niacin has versatile and substantial efficacy for the treatment of hyperlipidemias, but its utility is compromised by various side effects, the most serious of which is liver damage."3.70Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy. ( McCarty, MF, 2000)
"Niacin (nicotinic acid) is a widely used agent in the treatment of hyperlipidemias characterized by elevated low-density lipoprotein and very-low-density lipoprotein."3.68Hepatotoxicity associated with sustained-release niacin. ( Berry, RS; Dalton, TA, 1992)
" Adverse experiences (AEs) typically associated with niacin (flushing, pruritus, increased glucose, increased uric acid) were more common with ERN/LRPT+SIMVA, and hepatic-related laboratory AEs were more common with ATORVA."2.78Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia. ( Blomqvist, P; Chen, E; Chen, F; Davidson, M; Maccubbin, D; McKenney, JM; Sirah, W; Sisk, CM; Yan, L, 2013)
" The primary end point, the safety of E/S plus niacin, included prespecified adverse events (ie, liver, muscle, discontinuations due to flushing, gallbladder-related, cholecystectomy, fasting glucose changes, new-onset diabetes)."2.75Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia. ( Adewale, AJ; Fazio, S; Guyton, JR; Polis, AB; Ryan, NW; Tershakovec, AM; Tomassini, JE, 2010)
"Niacin treatment significantly increased TRL apoB-48 FCR but had no effect on apoB-48 PR."2.73Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins. ( Ai, M; Asztalos, BF; Barrett, PH; Buchsbaum, A; Diffenderfer, MR; Dolnikowski, GG; Horvath, KV; Lamon-Fava, S; Lichtenstein, AH; Matthan, NR; Nyaku, M; Otokozawa, S; Schaefer, EJ, 2008)
"Dyslipidemia is one of the main risk factors for atherosclerosis, usually the underlying cause of cardiovascular diseases which are the major cause of morbidity and mortality in developed countries."2.72Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects. ( Accinni, R; Bamonti, F; Bernacchi, F; Campolo, J; Caruso, R; Ciani, A; Della Noce, C; Ghersi, L; Gorini, M; Grossi, S; Ippolito, S; Lonati, S; Lorenzano, E; Novembrino, C; Rosina, M; Tonini, A, 2006)
"This review summarizes the role of hyperlipidemia in ASCVD and treatment strategies for hyperlipidemia in the CKD population."2.72Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. ( Bangalore, S; Chaudhry, R; Costa, SP; Lyubarova, R; Mathew, RO; Rosenson, RS; Sidhu, MS, 2021)
"Niacin ER/lovastatin was comparable to atorvastatin 10 mg and more effective than simvastatin 20 mg in reducing LDL cholesterol, was more effective in increasing HDL cholesterol than either atorvastatin or simvastatin, and provided greater global improvements in non-HDL cholesterol, triglycerides, and lipoprotein(a)."2.71Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]). ( Bays, HE; Crouse, JR; Dujovne, CA; Hutcheson, AG; Kashyap, ML; McGovern, ME; White, TE, 2003)
"Niacin ER/lovastatin was more effective than each of its components for improving levels of low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C), and triglycerides (TG), and exhibited a clear dose-response effect and additivity across the dosage range."2.71A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin. ( Brazg, R; Hunninghake, DB; Koren, M; McGovern, ME; Murdock, D; Pearson, T; Weiss, S, 2003)
"Patients with combined hyperlipidemia and low high-density lipoprotein (HDL) cholesterol levels may benefit from combination therapy with a statin and niacin; therefore, we assessed the efficacy and safety of rosuvastatin and extended-release (ER) niacin alone and in combination in 270 patients with this atherogenic dyslipidemia."2.71Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels. ( Capuzzi, DM; Chitra, RR; Cressman, MD; Hutchinson, HG; Morgan, JM; Weiss, RJ, 2003)
"This study compared efficacy of hyperlipidemia (HLE) correction by long-term hypolipidemic diet (HD) and pharmacotherapy (PT) in patients with ischemic heart disease (IHD)."2.71[Comparative efficiency of prolonged diet and drug therapies for hyperlipidemias in patients with ischemic heart disease]. ( Mal', GS, 2004)
" Patients in the southeast and those enrolled by endocrinologists had the lowest compliance and highest adverse event rates."2.71Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study. ( Rubenfire, M, 2004)
"ER-niacin's role in the treatment of antiretroviral therapy-associated dyslipidemia requires further evaluation, but the results of this pilot study indicate that it is safe and tolerated and provides a valuable treatment option."2.71Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy. ( Claxton, S; DeMarco, D; Drechsler, H; Gerber, MT; Mondy, KE; Powderly, WG; Stoneman, J; Tebas, P; Yarasheski, KE, 2004)
" The most common adverse event was flushing, which caused 10% of patients to withdraw."2.70Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia. ( Bays, HE; Berra, K; Favrot, LK; Guyton, JR; Harper, WL; Kashyap, ML; Kerzner, B; Kwiterovich, PO; McGovern, ME; Nash, SD; Simmons, PD; Toth, PD, 2002)
"In patients with atherogenic dyslipidemia, both drugs had important effects on lipoprotein subfractions, which contributed to a reduction in coronary heart disease risk."2.70Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia. ( Black, DM; McCormick, LS; McKenney, JM; Schaefer, EJ; Watkins, ML, 2001)
"Etofibrate is a hybrid drug which combines niacin with clofibrate."2.70Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects. ( Coelho, OR; Mansur, AP; Maranhão, RC; Ramires, JA; Rodrigues-Sobrinho, CR; Sposito, AC, 2001)
"Forty-nine middle-aged men with dyslipidemia and established CAD who were undergoing intensive lipid-lowering therapy were studied."2.70Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment. ( Brown, BG; Brunzell, JD; Deeb, SS; Hokanson, JE; Zambon, A, 2001)
" Rates of adverse event rates other than flushing were similar for the niacin and placebo groups."2.70Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial. ( Buse, JB; Fitz-Patrick, D; Ganda, OP; Grundy, SM; Kendall, DM; McGovern, ME; Robertson, DD; Rosenson, RS; Sheehan, JP; Tulloch, BR; Vega, GL, 2002)
" The most common adverse events were flushing and gastrointestinal disturbance."2.69Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia. ( Alagona, P; Capuzzi, DM; Goldberg, A; Guyton, J; Morgan, JM; Rodgers, J; Sachson, R; Samuel, P, 2000)
"Pravastatin treatment of combined hyperlipidemia lowers low-density lipoprotein effectively; nicotinic acid lowers remnant cholesterol and raises high-density lipoprotein."2.68Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia. ( Grundy, SM; Mostaza, JM; Schulz, I; Vega, GL, 1997)
"Acipimox was better tolerated than nicotinic acid but the percentage changes in lipoprotein concentrations were smaller."2.67The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover. ( Knight, BL; O'Connor, B; O'Donnell, M; Perombelon, N; Reaveley, D; Seed, M, 1993)
"Postprandial (non-fasting) hyperlipemia is characterized by increased blood levels of exogenous triglycerides (TG) in the form of apolipoprotein (apo) B48-containing TG-rich lipoproteins (TRL), which have a causal role in the pathogenesis and progression of cardiovascular disease (CVD)."2.53Pharmacological Effects of Niacin on Acute Hyperlipemia. ( Abia, R; Bermudez, B; la Paz, SM; Lopez, S; Muriana, FJ; Naranjo, MC, 2016)
"Niacin was the first hypolipidemic drug to significantly reduce both major cardiovascular events and mortality in patients with cardiovascular disease."2.53Pleiotropic effects of niacin: Current possibilities for its clinical use. ( Hrib, J; Hromádka, R; Perlík, F; Širc, J; Staňková, B; Tvrzická, E; Vecka, M; Žák, A; Zeman, M, 2016)
"Niacin is considered to be a powerful drug for the treatment of lipid and lipoprotein abnormalities connected with "residual cardiovascular risk", which persist in high-risk patients even when the target goals of LDL-C are achieved with statin therapy."2.52Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place? ( Hromádka, R; Perlík, F; Staňková, B; Tvrzická, E; Vecka, M; Žák, A; Zeman, M, 2015)
"Hyperlipidemia is common in dogs, and can be either primary or secondary to other diseases."2.46Lipid metabolism and hyperlipidemia in dogs. ( Steiner, JM; Xenoulis, PG, 2010)
"Fifth, combined hyperlipidemia is the most common lipid disorder, has the strongest risk for CVD, and combines elevated LDL, hypertriglyceridemia, and low HDL."2.44Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk. ( Atkinson, B; Dowdy, A; Knopp, RH; Paramsothy, P, 2008)
"Niacin has been used for decades in the treatment of patients with disturbed lipid and lipoprotein metabolism, this being the main cause of atherosclerotic changes in cardiovascular diseases."2.44[Niacin in therapy]. ( Bryła, J; Nagalski, A, 2007)
"Niacin has a substantial HDL-C raising effect, and also may beneficially alter total cholesterol, LDL-C and triglyceride levels."2.44Present-day uses of niacin: effects on lipid and non-lipid parameters. ( Karas, RH; Kuvin, JT; Sanyal, S, 2007)
"The approach to the management of hyperlipidemia has evolved dramatically over the past decade."2.43Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events. ( Balbisi, EA, 2006)
"Both diabetes and metabolic syndrome are associated with a clustering of cardiovascular risk factors."2.43Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. ( Betteridge, J; Shepherd, J; Van Gaal, L, 2005)
" The pharmacological dosage (approximately 0,5-4,5 g/day) substantially influences the plasma lipid and lipoprotein concentrations: decreases VLDL and LDL concentrations, changes the profile of LDL subfractions towards the larger particles as well as particles with lower density; it also profoundly increases the concentration of HDL-C in consequence of elevated concentration of HDL2 subfraction."2.43[Nicotinic acid: an unjustly neglected remedy]. ( Tvrzická, E; Vecka, M; Zák, A; Zeman, M, 2006)
"Dyslipidemia is characterized by increased triglyceride-rich lipoproteins; low high-density lipoprotein cholesterol; small, dense low-density lipoprotein particles; increased postprandial lipemia; and abnormal apolipoprotein A1 and B metabolism."2.42Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome. ( Cottrell, DA; Falko, JM; Marshall, BJ, 2003)
" Extended-release niacin, also given once daily, has an absorption rate intermediate between the other formulations and is associated with fewer flushing and gastrointestinal symptoms without increasing hepatotoxic risk."2.42New perspectives on the use of niacin in the treatment of lipid disorders. ( McKenney, J, 2004)
"Niacin promotes angiographic regression when used in combination with other drugs that lower LDL cholesterol and can reduce cardiovascular risk in patients with coronary heart disease."2.42Clinical update on the use of niacin for the treatment of dyslipidemia. ( Berra, K, 2004)
"Niacin has been known to be an effective treatment of dyslipidemia for almost half a century."2.42Niacin as a component of combination therapy for dyslipidemia. ( Miller, M, 2003)
"Niacin has long been known to improve concentrations of all major lipids and lipoproteins, but it also has consistently favorable effects on subclass distribution."2.42The effects of niacin on lipoprotein subclass distribution. ( Capuzzi, DM; Carey, CM; Lincoff, A; Morgan, JM, 2004)
"Niacin ER has been studied extensively in combination therapy with statins, including lovastatin in a recently introduced combination tablet."2.42Extended-release niacin for modifying the lipoprotein profile. ( Guyton, JR, 2004)
"Treatment of the dyslipidemia associated with type 2 diabetes and FCHL with a combination of a statin and a thiazolidinedione or niacin offers the most comprehensive modality to correct the various lipid abnormalities."2.42Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia. ( Ayyobi, AF; Brunzell, JD, 2003)
"However, many patients with dyslipidemia who have or are at risk for CHD do not reach target LDL-C goals."2.42Therapy to reduce risk of coronary heart disease. ( Rader, DJ, 2003)
"Patients with dyslipidemias continue to be undertreated in both the primary and secondary prevention settings."2.42Combination therapy in the management of complex dyslipidemias. ( Davidson, MH; Toth, PP, 2004)
"Niacin has multifarious lipoprotein and anti-atherothrombosis effects that improve endothelial function, reduce inflammation, increase plaque stability, and diminish thrombosis."2.42Antiatherothrombotic effects of nicotinic acid. ( Rosenson, RS, 2003)
"Niacin is an inexpensive drug useful in treating various forms of hyperlipidemia."2.41Use of niacin in the prevention and management of hyperlipidemia. ( Arnold, G; Robinson, AW; Sloan, HL, 2001)
" In addition, there have been preclinical reports suggesting the potential usefulness of orally bioavailable inhibitors of cholesterol ester transfer protein in plasma and of acylcoA:cholesterol acyltransferase in monocyte-macrophages."2.41Novel lipid-regulating drugs. ( Naoumova, RP; Thompson, GR, 2000)
"The characteristic dyslipidemia of insulin resistance consists of elevated triglyceride and triglyceride-rich lipoprotein levels, low levels of high-density lipoprotein cholesterol, and increased concentrations of small, dense low-density lipoprotein cholesterol."2.41Pathophysiology and treatment of the dyslipidemia of insulin resistance. ( Capuzzi , DM; Cohn, G; Valdes, G, 2001)
" These issues of possible harm or lack of benefit from long-term use of lipid-lowering therapy, and cost effectiveness, are also pertinent in the pediatric setting."2.41Should pediatric patients with hyperlipidemia receive drug therapy? ( Bhatnagar, D, 2002)
"Patients with combined dyslipidemia are at high risk for coronary artery disease and often require combination drug therapy to achieve lipid levels recommended by the US National Cholesterol Education Program's third Adult Treatment Panel (ATP III)."2.41Combination therapy for combined dyslipidemia. ( Ballantyne, CM; Xydakis, AM, 2002)
"Niacin is an important therapeutic option for the treatment of dyslipidemias and is the only agent currently available that favorably affects all components of the lipid profile to a significant degree."2.41Understanding niacin formulations. ( Pieper, JA, 2002)
"Combination therapy for hyperlipidemia, especially combined hyperlipidemia, may have advantages over single drug therapy, affording better improvement in lipoprotein risk factors and possibly better prevention of atherothrombotic events."2.40Combination drug therapy for combined hyperlipidemia. ( Guyton, JR, 1999)
"The niacin-statin treatment regimens gave augmented low-density lipoprotein (LDL)-cholesterol reduction along with favorable changes in high-density lipoprotein (HDL) cholesterol, lipoprotein(a), and triglycerides."2.40Treatment of hyperlipidemia with combined niacin-statin regimens. ( Capuzzi, DM; Guyton, JR, 1998)
"Treatment of dyslipidemia to prevent CHD depends on the pattern and severity of dyslipidemia, the presence of overt CHD, and the patient's response to diet."2.40Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease. ( Borgia, MC; Medici, F, 1998)
"Effective treatment of dyslipidemia improves prognosis."2.40Combination drug therapy for dyslipidemia. ( Alaswad, K; Moe, RM; O'Keefe, JH, 1999)
"Niacin can be very effective and safe in lowering low-density lipoprotein cholesterol and triglyceride levels and also in increasing high-density lipoprotein cholesterol levels."2.39Niacin for lipid disorders. Indications, effectiveness, and safety. ( Brown, WV, 1995)
"Several forms of dyslipidemia are associated with premature coronary artery disease (CAD) and other vascular disease."2.39Hyperlipidemia: perspectives in diagnosis and treatment. ( Gotto, AM; Yeshurun, D, 1995)
"Recent studies suggest that treating dyslipidemia in persons with coronary atherosclerosis may decrease morbidity and mortality."2.39Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy. ( Rembold, CM, 1996)
"Niacin has a long history of use as a lipid lowering agent and has several attractive features."2.39New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug. ( Crouse, JR, 1996)
" Careful dosing titration may, however, minimize these effects."2.37Nicotinic acid: a review of its clinical use in the treatment of lipid disorders. ( Figge, HL; Figge, J; Mutnick, AH; Sacks, F; Souney, PF, 1988)
"Hyperlipidemia should be managed systematically using information about the association between increased lipid concentrations and CAD, patient risk factors, and limitations of both diet and drug therapy."2.37Contemporary recommendations for evaluating and treating hyperlipidemia. ( Perry, RS, 1986)
"The Heart Protection Study 2-Treatment of HDL to Reduce the Incidence of Vascular Events (HPS2-THRIVE) trial found higher incidence rates of adverse reactions, including bleeding, in patients receiving the combination of extended-release niacin and laropiprant versus placebo."1.48Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system. ( Gagne, JJ; Hampp, C; Houstoun, M; Marshall, JH; Reichman, ME; Toh, S, 2018)
"Hyperlipidemia treatment based on niacin requires gastrointestinal administration of relatively high doses."1.42The use of a hydrogel matrix for controlled delivery of niacin to the gastrointestinal tract for treatment of hyperlipidemia. ( Hobzova, R; Hrib, J; Hromadka, R; Michalek, J; Sandrikova, V; Sirc, J; Slanar, O; Stankova, B; Vetrik, M; Zak, A, 2015)
"High-fat diet induced hyperlipidemia and obesity in immature rats."1.39[Relationship of ox-LDL/LOX-1 and vascular endothelial dysfunction of diet-induced obese immature rats and nicotinic acid's intervention outcomes]. ( Han, B; Niu, N; Sun, SZ; Wang, Y, 2013)
"Multiple-drug therapy of dyslipidemia is frequently used to achieve treatment goals in high-risk patients with coronary artery disease."1.36LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol. ( Phillips, W; Schaefer, S, 2010)
"Niacin is a unique lipid-lowering medication with a capacity to lower low-density lipoprotein cholesterol (LDL-c), triglyceride and increase HDL-c."1.36What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease? ( Ahmed, MH, 2010)
" Treatment with prolonged-release nicotinic acid was initiated according to the approved dosing regimen."1.35[Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France]. ( Mosnier, M; Paillard, F, 2008)
" Since DDIs are associated with adverse reactions, we performed a cross-sectional study to assess the prevalence of potentially critical drug-drug and drug-statin interactions in an outpatient adult population with dyslipidaemia."1.33Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy. ( Hess, L; Krähenbühl, S; Krähenbühl-Melcher, A; Rätz Bravo, AE; Schlienger, RG; Tchambaz, L, 2005)
"Niacin has been used for decades for the treatment of dyslipidemia because of its favorable effects on all lipoprotein parameters."1.32Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety. ( Pieper, JA, 2003)
"Also dyslipidemia seems to be involved in enzyme activity variations of the tryptophan metabolism along the kynurenine pathway."1.31Enzyme activities along the tryptophan-nicotinic acid pathway in alloxan diabetic rabbits. ( Allegri, G; Bertazzo, A; Biasiolo, M; Caparrotta, L; Costa, CV; Ragazzi, E, 2002)
" Because a slow-release matrix tablet of the drug combination resulted in a similar magnitude of effect as the IGI administration, the present study provides a pharmacodynamic rationale for the use of a slow-release low-dose niacin-bezafibrate combination."1.31Pharmacodynamic effects of bezafibrate and niacin combination: implications of the mode of administration. ( Friedman, M; Haimov, T; Hoffman, A; Lomnicky, Y; Luria, MH, 2000)
"Niaspan, when added to a stable dose of a statin in 66 subjects, was found to be safe and highly effective in improving lipid parameters."1.31Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia. ( Bansavich, LL; Friedrich, CA; Meagher, E; Mohler, ER; Rader, DJ; Ross, JL; Vartanian, SF; Wolfe, ML, 2001)
" Successful and safe therapy requires ongoing supervision and instruction by qualified health care providers to monitor the efficacy of therapy and minimize niacin's potential for adverse effects."1.30ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists. ( , 1997)
"13 patients aged 39 to 60 years with coronary atherosclerosis confirmed at selective coronary angiography combined with primary hyperlipidemia (phenotypes 2a and 2b) received enduracin in a dose 1500 mg/day."1.30[The effect of long-term Enduracin monotherapy on the clinical and biochemical status of patients with ischemic heart disease]. ( Aronskaia, EE; Kukharchuk, VV; Malyshev, PP; Rozhkova, TA; Semenova, OA; Solov'ev, EIu, 1997)
"Niacin use was associated with a 16."1.30Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization. ( O'Connor, PJ; Rush, WA; Trence, DL, 1997)
"Bezafibrate was effective hypolipidemic agent in normal rats, but addition of nicotinic acid has certainly improved the effectiveness further which could be of clinical significance."1.28Effect of bezafibrate & nicotinic acid on triton induced hyperlipidemias in CFY rats. ( Krishnamurthy, A; Thapar, GS, 1991)
" This manifestation of hepatotoxicity seems to differ from that previously reported in association with use of crystalline niacin, which occurred with high dosage and prolonged usage of the medication."1.28Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin. ( Allison, TG; Etchason, JA; Gau, GT; Kottke, BA; Marttila, JK; Miller, TD; Squires, RW, 1991)
" Most of these drugs have side effects which, in the elderly, may necessitate lower dosing than usual."1.27Treating hyperlipidemia, Part III: Drug therapy. ( Brown, WV; Karmally, W; Smith, DA, 1987)
"Experimental hyperlipidemia was induced in ddY, C57BL, BALB and ICR strain mice and in Wistar rats."1.27[Strains and species differences in experimental hyperlipidemia]. ( Hirai, Y; Kawakami, M; Koyama, S; Mishima, Y; Mizutani, A; Morishita, S; Saito, T, 1986)
"Probucol has a sustained effect, additive to that of a lipid-lowering diet; it can reduce total serum cholesterol and cause xanthoma regression even in patients with receptor-defective homozygous familial hypercholesterolemia."1.27Medical management of hyperlipidemia and the role of probucol. ( Davignon, J, 1986)
" Adverse side effects ranging from mere annoyances to uncommon serious consequences may be associated with dietary modification, recreational physical exercise, and drug intervention."1.27Adverse effects of the treatment for hyperlipidemia. ( Malinow, MR, 1986)

Research

Studies (299)

TimeframeStudies, this research(%)All Research%
pre-199046 (15.38)18.7374
1990's67 (22.41)18.2507
2000's145 (48.49)29.6817
2010's40 (13.38)24.3611
2020's1 (0.33)2.80

Authors

AuthorsStudies
Wise, A1
Foord, SM1
Fraser, NJ1
Barnes, AA1
Elshourbagy, N1
Eilert, M1
Ignar, DM1
Murdock, PR1
Steplewski, K1
Green, A1
Brown, AJ1
Dowell, SJ1
Szekeres, PG1
Hassall, DG1
Marshall, FH1
Wilson, S1
Pike, NB1
Mathew, RO1
Rosenson, RS6
Lyubarova, R1
Chaudhry, R1
Costa, SP1
Bangalore, S1
Sidhu, MS1
Skolnik, N1
Jaffa, FM1
Kalyani, RR1
Johnson, E1
Shubrook, JH1
Ferchaud-Roucher, V1
Croyal, M1
Moyon, T1
Zair, Y1
Krempf, M1
Ouguerram, K1
Gagne, JJ1
Houstoun, M1
Reichman, ME1
Hampp, C1
Marshall, JH1
Toh, S1
Xie, YD1
Chen, ZZ1
Li, N1
Lu, WF1
Xu, YH1
Lin, YY1
Shao, LH1
Wang, QT1
Guo, LY1
Gao, YQ1
Yang, GD1
Li, YP1
Bian, XL1
Cai, S1
Liu, TYA1
Arevalo, JF1
Nicholls, SJ1
Andrews, J1
Duong, M1
Gillard, BK1
Raya, JL1
Ruiz-Esponda, R1
Iyer, D1
Coraza, I1
Balasubramanyam, A2
Pownall, HJ2
Nofer, JR1
Le, NA1
Jin, R1
Tomassini, JE4
Tershakovec, AM4
Neff, DR1
Wilson, PW1
Niu, N2
Sun, SZ1
Han, B1
Wang, Y2
Zafrir, B1
Jain, M1
Nesan, D1
Ng, DS2
Heemskerk, MM1
Dharuri, HK1
van den Berg, SA1
Jónasdóttir, HS1
Kloos, DP1
Giera, M1
van Dijk, KW1
van Harmelen, V1
Zeman, M3
Vecka, M3
Perlík, F2
Hromádka, R3
Staňková, B3
Tvrzická, E3
Žák, A4
Sirc, J2
Hrib, J2
Vetrik, M1
Hobzova, R1
Slanar, O1
Sandrikova, V1
Michalek, J1
Bittner, V1
Deng, L1
Taylor, B1
Glasser, SP1
Kent, ST1
Farkouh, ME1
Muntner, P1
la Paz, SM1
Bermudez, B1
Naranjo, MC1
Lopez, S1
Abia, R1
Muriana, FJ1
Rahimy, E1
Gaynon, MW1
Paulus, YM1
Alexander, JL1
Mansour, SE1
Brinton, EA1
Triscari, J1
Brudi, P1
Chen, E2
Johnson-Levonas, AO1
Sisk, CM2
Ruck, RA1
MacLean, AA1
Maccubbin, D2
Mitchel, YB1
Lamon-Fava, S1
Diffenderfer, MR1
Barrett, PH1
Buchsbaum, A1
Nyaku, M1
Horvath, KV1
Asztalos, BF1
Otokozawa, S1
Ai, M1
Matthan, NR1
Lichtenstein, AH1
Dolnikowski, GG1
Schaefer, EJ2
Svilaas, A1
Strandberg, T1
Eriksson, M1
Hildebrandt, P1
Westheim, A1
Yu, YH1
Wang, LJ1
Li, Q1
Guo, LM1
Robinson, JG1
Guthrie, R1
Ansell, BJ2
Jones, PH4
Xenoulis, PG1
Steiner, JM1
Hou, R1
Goldberg, AC3
Kole, LA1
Fazio, S3
Guyton, JR9
Polis, AB1
Adewale, AJ2
Ryan, NW1
Phillips, W1
Schaefer, S1
Choudhury, RP1
Virani, SS1
Ballantyne, CM4
Ahmed, MH1
Lin, J1
Shah, A2
Kamerath, JH1
De Luigi, AJ1
Döger, MM6
Sokmen, BB2
Yanardag, R6
Insull, W1
Toth, PP2
Superko, HR2
Thakkar, RB1
Krause, S1
Jiang, P1
Parreno, RA1
Padley, RJ1
Qandil, AM1
Rezigue, MM1
Tashtoush, BM1
Chen, F1
Yan, L1
Sirah, W1
Davidson, M2
Blomqvist, P1
McKenney, JM3
Jensen, E1
Shah, MK1
Critchley, WR1
Yonan, N1
Williams, SG1
Shaw, SM1
Julius, U1
Fischer, S1
Grundy, SM6
Vega, GL3
McGovern, ME5
Tulloch, BR1
Kendall, DM1
Fitz-Patrick, D1
Ganda, OP1
Buse, JB1
Robertson, DD1
Sheehan, JP1
Pieper, JA3
Ito, MK4
Barter, P1
Packard, C1
Olsson, AG2
Stone, NJ2
McKenney, J3
Xydakis, AM2
Bays, H1
Brown, AS1
Davidson, MH4
Moon, YS1
Kashyap, ML5
Duvall, WL1
Blazing, MA1
Saxena, S1
Stein, EA2
Yim, BT1
Chong, PH1
Rader, DJ2
Mikhail, N1
Bays, HE4
Dujovne, CA1
White, TE1
Hutcheson, AG1
Crouse, JR2
Hunninghake, DB2
Koren, M2
Brazg, R1
Murdock, D1
Weiss, S2
Pearson, T1
Capuzzi, DM6
Morgan, JM5
Weiss, RJ1
Chitra, RR1
Hutchinson, HG1
Cressman, MD2
Kastelein, J1
Ryan, MJ1
Gibson, J1
Simmons, P1
Stanek, E1
Cottrell, DA1
Marshall, BJ1
Falko, JM1
Talbert, RL2
Miller, M1
Ayyobi, AF1
Brunzell, JD3
BELLE, M1
HALPERN, MM1
DAVIS, OF1
BECK, C1
BERGAL, M1
SLOAN, N1
LEVINE, AJ1
HOLLOMAN, JL1
DAVIS, CC1
LEEPER, LC1
TRIBIANO, CW1
SPENCER, JL1
WADDELL, WR1
HURLEY, N1
FIELD, RA1
KNUECHEL, F1
FITZGERALD, O1
HEFFERNAN, A1
BRENNAN, P1
MULCAHY, R1
FENNELLY, JJ1
MCFARLANE, R1
FAIVRE, G1
GILGENKRANTZ, JM1
CHERRIER, F1
HENRY, C1
YASUGI, T1
SCHOEN, H4
ZELLER, W2
HENNING, N1
ILIESCU, M1
DOMOCOS, G1
IACOBINI, P1
CONSTANTINESCU, S1
ILIESCU, CC1
NEUMANN, J1
STUETTGEN, G1
LEUTIGER, H1
WENNERBY, S1
VASTESAEGER, MM1
CALI, G1
PIETROPAOLO, C1
FIORENTINO, E1
AURITI, R1
BODE, G1
GRIMM, B1
Thompson, PD1
Kolovou, GD1
Daskalova, DC1
Petropoulos, II1
Anagnostopoulou, KK1
Bilianou, HI1
Pilatis, ND1
Pavlidis, AN1
Cokkinos, DV1
Meyers, CD1
Carr, MC1
Park, S1
Dib, JG1
Dedeyan, S1
Dierkes, J1
Westphal, S2
Luley, C2
Malik, S1
Streja, D1
Mal', GS1
Rubenfire, M1
Gerber, MT1
Mondy, KE1
Yarasheski, KE1
Drechsler, H1
Claxton, S1
Stoneman, J1
DeMarco, D1
Powderly, WG1
Tebas, P1
Carlson, LA3
Ascaso, JF1
Fernández-Cruz, A1
González Santos, P1
Hernández Mijares, A1
Mangas Rojas, A1
Millán, J1
Felipe Pallardo, L1
Pedro-Botet, J1
Pérez-Jiménez, F1
Pía, G1
Pintó, X1
Plaza, I1
Rubiés-Prat, J1
Nicholls, S1
Lundman, P1
Meagher, EA1
Carey, CM2
Intenzo, C1
Tulenko, T1
Kearney, D1
Walker, K1
Lincoff, A1
Bolkent, S4
Benz, R1
Suter, PM1
Berra, K2
Backes, JM1
Gibson, CA1
Rätz Bravo, AE1
Tchambaz, L1
Krähenbühl-Melcher, A1
Hess, L1
Schlienger, RG1
Krähenbühl, S1
Asano, M1
Yamada, N1
Foley, SM1
Peksel, A2
Yesilyaprak, B1
Arisan-Atac, I1
Wieneke, H1
Schmermund, A1
Erbel, R1
Reasner, CA1
Cater, NB1
Meguro, S1
Shepherd, J3
Betteridge, J1
Van Gaal, L1
Ragazzi, E2
Costa, CV2
Comai, S1
Bertazzo, A2
Caparrotta, L2
Allegri, G2
Parhofer, KG1
Ducobu, J1
Balbisi, EA1
Accinni, R1
Rosina, M1
Bamonti, F1
Della Noce, C1
Tonini, A1
Bernacchi, F1
Campolo, J1
Caruso, R1
Novembrino, C1
Ghersi, L1
Lonati, S1
Grossi, S1
Ippolito, S1
Lorenzano, E1
Ciani, A1
Gorini, M1
Samson, SL1
Scott, LW2
Smith, EO1
Sekhar, RV1
Atac, IA1
Bilen, ZG1
Borucki, K1
Taneva, E1
Makarova, R1
Inceli, MS1
Li, XP1
Duan, J1
Zhao, SP2
Tan, MY1
Xu, ZM1
Zhang, DQ1
Yuvaraj, S1
Premkumar, VG1
Vijayasarathy, K1
Gangadaran, SG1
Sachdanandam, P1
Broncel, M1
Balcerak, M1
Chojnowska-Jezierska, J2
Nagalski, A1
Bryła, J1
Sanyal, S1
Karas, RH1
Kuvin, JT1
Gille, A1
Bodor, ET1
Ahmed, K1
Offermanns, S1
Athyros, VG1
Tziomalos, K1
Mikhailidis, DP1
Pagourelias, ED1
Kakafika, AI1
Skaperdas, A1
Hatzitolios, A1
Karagiannis, A1
Suren Castillo, S1
Bouknight, P1
Mackler, L1
Heffington, M1
Yang, J1
Li, J1
Wu, ZH1
Dong, SZ1
Drexel, H1
Aronow, WS1
Nampurath, GK1
Mathew, SP1
Khanna, V1
Zachariah, RT1
Kanji, S1
Chamallamudi, MR1
Restrepo Valencia, CA1
Cruz, J1
Knopp, RH6
Paramsothy, P1
Atkinson, B1
Dowdy, A2
Brown, BG3
Zhao, XQ2
Paillard, F1
Mosnier, M1
Blankenhorn, DH1
Azen, SP1
Nessim, SA1
Pyrig, LA1
Petrun, NM1
Nikulina, GG1
Gorelova, NR1
Nash, DT1
Smith, SR1
Havel, RJ1
Kane, JP2
Gustafsson, K1
Kiessling, H1
Gibbons, LW1
Gonzalez, V1
Gordon, N1
Grundy, S1
Tsalamandris, C1
Panagiotopoulos, S1
Sinha, A1
Cooper, ME1
Jerums, G1
Brown, WV2
Lal, SM1
Hewett, JE1
Petroski, GF1
Van Stone, JC1
Ross, G1
Yeshurun, D1
Gotto, AM4
Shakir, KM1
Kroll, S1
Aprill, BS1
Drake, AJ1
Eisold, JF1
Morales, E1
Spinler, SA1
Wilson, MD1
Chin, MM1
Jozefiak, E1
Fraunfelder, FW1
Fraunfelder, FT1
Illingworth, DR2
Gharavi, AG1
Diamond, JA1
Smith, DA2
Phillips, RA1
Kreisberg, RA1
Kuo, PT1
Felicetta, JV1
Seed, M1
O'Connor, B1
Perombelon, N1
O'Donnell, M1
Reaveley, D1
Knight, BL1
Wahlberg, G2
Walldius, G2
Rembold, CM1
Mann, WA1
Windler, E1
Beil, FU1
Greten, H1
Spencer, GA1
Wirebaugh, S1
Whitney, EJ2
Schiel, R1
Bambauer, R1
Müller, UA1
Farmer, JA1
Aronov, DM1
O'Connor, PJ1
Rush, WA1
Trence, DL1
Mostaza, JM1
Schulz, I1
Bardsley, J1
Poulin, D1
Hillger, LA1
Maher, VM1
Albers, JJ2
Andrews, TC1
Green, G1
Kalenian, R1
Personius, BE1
Kukharchuk, VV1
Solov'ev, EIu1
Malyshev, PP1
Rozhkova, TA1
Semenova, OA1
Aronskaia, EE1
Schuna, AA1
McCormick, LS2
Kafonek, S1
Black, DM2
Borgia, MC1
Medici, F1
Adamska-Dyniewska, H1
Krause, BR1
Princen, HM1
Alagona, P2
Kafonek, SD1
Kashyap, M1
Sprecher, D1
Jenkins, S1
Marcovina, S1
Leighton, RF1
Gordon, NF1
Small, GS1
Davis, WJ1
Ward, ES1
Lomnicky, Y2
Friedman, M2
Luria, MH2
Raz, I1
Hoffman, A2
Smolenskaia, OG1
Kazakov, IaE1
Barats, SS1
Gylys, KH1
Sikand, G1
Wong, ND1
Hsu, JC1
Goldberg, A1
Guyton, J1
Rodgers, J1
Sachson, R1
Samuel, P1
Haimov, T1
McCarty, MF1
Thompson, GR1
Naoumova, RP1
Alaswad, K1
O'Keefe, JH1
Moe, RM1
Zambon, A1
Deeb, SS1
Hokanson, JE1
Sposito, AC1
Mansur, AP1
Maranhão, RC1
Rodrigues-Sobrinho, CR1
Coelho, OR1
Ramires, JA1
Wolfe, ML1
Vartanian, SF1
Ross, JL1
Bansavich, LL1
Mohler, ER1
Meagher, E1
Friedrich, CA1
Cía Gómez, P1
Robinson, AW1
Sloan, HL1
Arnold, G1
Onuma, T1
Kawamori, R1
Ogaki, S1
Matsushima, T1
Legato, MJ1
Pearson, TA1
Smith, SC1
Watkins, ML1
Jacobson, TA1
Cohn, G1
Valdes, G1
Capuzzi , DM1
Busquets, S1
Carbó, N1
Almendro, V1
Figueras, M1
López-Soriano, FJ1
Argilés, JM1
Taher, TH1
Dzavik, V1
Reteff, EM1
Pearson, GJ1
Woloschuk, BL1
Francis, GA1
Wink, J1
Giacoppe, G1
King, J1
Kwiterovich, PO1
Harper, WL1
Toth, PD1
Favrot, LK1
Kerzner, B1
Nash, SD1
Simmons, PD1
Bhatnagar, D1
Klungel, OH1
Heckbert, SR1
de Boer, A1
Leufkens, HG1
Sullivan, SD1
Fishman, PA1
Veenstra, DL1
Psaty, BM1
Biasiolo, M1
Ruhn, G2
Prihoda, JS1
Bassler, TJ1
Keenan, JM1
Wenz, JB1
Ripsin, CM1
Huang, Z1
McCaffrey, DJ1
O'Kane, MJ1
Trinick, TR1
Tynan, MB1
Trimble, ER1
Nicholls, DP1
Dalton, TA1
Berry, RS1
Steiner, G1
Whelan, AM1
Price, SO1
Fowler, SF1
Hainer, BL1
Krishnamurthy, A1
Thapar, GS1
DiPalma, JR1
Thayer, WS1
Palumbo, PJ1
Etchason, JA1
Miller, TD1
Squires, RW1
Allison, TG1
Gau, GT1
Marttila, JK1
Kottke, BA1
Earthman, TP1
Odom, L1
Mullins, CA1
Szamosi, A1
Simpson, H1
Williamson, CM1
Pringle, S1
MacLean, J1
Lorimer, AR1
Packard, CJ2
Johansson, J1
Erikson, U1
Figge, HL1
Figge, J1
Souney, PF1
Mutnick, AH1
Sacks, F1
Karmally, W1
Olivier, P1
Plancke, MO1
Marzin, D1
Clavey, V1
Sauzieres, J1
Fruchart, JC1
Goldstein, MR1
Malloy, MJ1
Naito, HK1
Morishita, S1
Saito, T1
Mishima, Y1
Mizutani, A1
Hirai, Y1
Koyama, S1
Kawakami, M1
Davignon, J1
Tikkanen, MJ1
Nikkilä, EA1
Perry, RS1
Malinow, MR1
Stuyt, PM1
Noseda, G1
Cohen, M1
Ginsberg, J1
Hoff, C1
Ogilvie, JT1
Warnick, GR1
Burrows, E1
Retzlaff, B1
Poole, M1
Postnikova, NV1
Vasilenko, IuK1
Cherevatyĭ, VS1
Parker, F1

Clinical Trials (11)

Trial Overview

TrialPhaseEnrollmentStudy TypeStart DateStatus
Metabolic Effects of an 8 Week Niaspan Treatment in Patients With Abdominal Obesity and Mixed Dyslipidemia[NCT01216956]24 participants (Actual)Interventional2006-09-30Completed
Diet/Exercise, Niacin, Fenofibrate for HIV Lipodystrophy[NCT00246376]221 participants (Actual)Interventional2004-01-31Completed
Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb Hyperlipidemia[NCT00271817]Phase 31,220 participants (Actual)Interventional2005-12-31Completed
A Multicenter, Randomized, Double-Blind, Parallel Group, 12 Week Study to Evaluate the Efficacy and Safety of MK0524B Versus Atorvastatin in Patients With Mixed Hyperlipidemia[NCT00289900]Phase 32,340 participants (Actual)Interventional2006-01-24Completed
Randomized, Double-blind, Placebo-controlled Trial of Niaspan® in Patients With Overt Diabetic Nephropathy and Moderate Renal Impairment[NCT00108485]Phase 39 participants (Actual)Interventional2005-04-30Terminated (stopped due to Unable to recruit sufficient study subjects)
[NCT00006295]370 participants (Anticipated)Observational2000-08-31Completed
Effects of Ezetimibe in Association With Statins on Postprandial Lipemia in Type 2 Diabetic Patients[NCT00699023]Phase 413 participants (Anticipated)Interventional2008-06-30Completed
A Prospective, Open Label Comparison of Ezetimibe, Niacin, and Colestipol as Adjunct Therapy in Lipid Reduction[NCT00203476]Phase 430 participants (Actual)Interventional2005-05-31Completed
Human Lipoprotein Pathophysiology - Subproject: Genetics of Familial Combined Hyperlipidemia[NCT00005313]450 participants (Actual)Observational2001-04-30Completed
A Multicenter Study Of Nutraceutical Drinks For Cholesterol (Evaluating Effectiveness and Tolerability)[NCT01152073]79 participants (Actual)Interventional2009-10-31Completed
The Effect of Ezetimibe 10 mg, Simvastatin 20 mg and the Combination of Simvastatin 20 mg Plus 10 mg Ezetimibe on Low Density Lipoprotein (LDL)-Subfractions in Patients With Type 2 Diabetes[NCT01384058]Phase 441 participants (Actual)Interventional2007-11-30Completed
[information is prepared from clinicaltrials.gov, extracted Sep-2024]

Trial Outcomes

HDL-C

HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care37.1
Group 2 - Diet/Exercise Only38.7
Group 3 - Diet/Exercise + Fenofibrate40.7
Group 4 - Diet/Exercise + Niacin41.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin44.8

Non-HDL-C

non-HDL-C (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dl (Mean)
Group 1 - Usual Care162.2
Group 2 - Diet/Exercise Only165.4
Group 3 - Diet/Exercise + Fenofibrate145.8
Group 4 - Diet/Exercise + Niacin154
Group 5 - Diet/Exercise + Fenofibrate + Niacin137.1

Total Cholesterol

Total cholesterol (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care195.6
Group 2 - Diet/Exercise Only200.1
Group 3 - Diet/Exercise + Fenofibrate184
Group 4 - Diet/Exercise + Niacin190.8
Group 5 - Diet/Exercise + Fenofibrate + Niacin178.4

Total Cholesterol : HDL-C Ratio

Total cholesterol : HDL-C ratio: Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionratio (Mean)
Group 1 - Usual Care5.2
Group 2 - Diet/Exercise Only5.1
Group 3 - Diet/Exercise + Fenofibrate4.5
Group 4 - Diet/Exercise + Niacin4.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin4

Triglycerides

Triglycerides (mg/dL): Fasting lipid levels (NCT00246376)
Timeframe: Measured at 24 weeks

Interventionmg/dL (Mean)
Group 1 - Usual Care199
Group 2 - Diet/Exercise Only216.9
Group 3 - Diet/Exercise + Fenofibrate155.1
Group 4 - Diet/Exercise + Niacin177.6
Group 5 - Diet/Exercise + Fenofibrate + Niacin135.6

Body Composition

"Body cell mass (kg)~Fat mass (kg)" (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionkg (Mean)
Body cell massFat mass
Group 1 - Usual Care59.636.8
Group 2 - Diet/Exercise67.337.5
Group 3 - Diet/Exercise + Fenofibrate66.635.8
Group 4 - Diet/Exercise + Niacin67.137.7
Group 5 - Diet/Exercise + Fenofibrate + Niacin68.236.2

Insulin Sensitivity

Adiponectin (micrograms/ml) (NCT00246376)
Timeframe: Measured at 24 weeks

,,,,
Interventionmicrograms/ml (Mean)
Fasting insulinHOMA-IRInsulin sensitvity indexAdiponectin
Group 1 - Usual Care8.71.923.547.12
Group 2 - Diet/Exercise Only6.71.384.956.04
Group 3 - Diet/Exercise + Fenofibrate9.52.023.815.24
Group 4 - Diet/Exercise + Niacin11.92.762.8811.01
Group 5 - Diet/Exercise + Fenofibrate + Niacin10.32.382.3810.34

Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin8.1
Ezetimibe/Simvastatin + Niacin30.2

Percent Change From Baseline in High-Density Lipoprotein-Cholesterol (HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in HDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin9.0
Ezetimibe/Simvastatin + Niacin30.5

Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin-53.5
Ezetimibe/Simvastatin + Niacin-58.5

Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in LDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin-49.3
Ezetimibe/Simvastatin + Niacin-54.0

Percent Change From Baseline in Low-Density Lipoprotein-Cholesterol (LDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change, from baseline in LDL-C after 24 weeks - 24 Week Measure Minus Baseline (NCT00271817)
Timeframe: Baseline and 24 Weeks

InterventionPercent change (Mean)
Niacin-20.1
Ezetimibe/Simvastatin + Niacin-58.5

Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin-47.9
Ezetimibe/Simvastatin + Niacin-55.6

Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in non-HDL-C after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks

InterventionPercent change (Mean)
Ezetimibe/Simvastatin-45.1
Ezetimibe/Simvastatin + Niacin-52.4

Percent Change From Baseline in Non-High-Density Lipoprotein-Cholesterol (Non-HDL-C)

Ezetimibe/simvastatin co-administered with niacin extended release compared to niacin extended release monotherapy on the percent change from baseline in non-HDL-C after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 24 weeks

InterventionPercent change (Mean)
Niacin-22.0
Ezetimibe/Simvastatin + Niacin-55.6

Percent Change From Baseline in Triglycerides (TG)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 24 weeks - 24 week measure minus baseline (NCT00271817)
Timeframe: baseline and 24 Weeks

InterventionPercent change (Median)
Ezetimibe/Simvastatin23.7
Ezetimibe/Simvastatin + Niacin-42.5

Percent Change From Baseline in Triglycerides (TG)

Ezetimibe/simvastatin co-administered with niacin extended release compared to ezetimibe/simvastatin monotherapy on the percent change from baseline in Triglycerides after 64 weeks - 64 week measure minus baseline (NCT00271817)
Timeframe: Baseline and 64 weeks

InterventionPercent change (Median)
Ezetimibe/Simvastatin-26.8
Ezetimibe/Simvastatin + Niacin-44.5

Percentage Change From Baseline in Apo A-I

Blood samples taken at baseline and after 12 weeks of treatment to determine the Apo A-I levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage change (Least Squares Mean)
MK-0524B 2g/20 mg10.7
MK-0524B 2g/40mg8.2
Atorvastatin 10 mg1.7
Atorvastatin 20 mg0.4
Atorvastatin 40 mg-0.8
Atorvastatin 80 mg-2.5

Percentage Change From Baseline in Apolipoprotein (Apo) B

Blood samples taken at baseline and after 12 weeks of treatment to determine the Apo B levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage change (Least Squares Mean)
MK-0524B 2g/20 mg-36.1
MK-0524B 2g/40mg-38.0
Atorvastatin 10 mg-26.9
Atorvastatin 20 mg-32.8
Atorvastatin 40 mg-37.2
Atorvastatin 80 mg-38.3

Percentage Change From Baseline in C-reactive Protein (CRP)

Blood samples taken at baseline and after 12 weeks of treatment to determine the CRP levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage change (Median)
MK-0524B 2g/20 mg-15.4
MK-0524B 2g/40mg-20.0
Atorvastatin 10 mg-19.5
Atorvastatin 20 mg-28.6
Atorvastatin 40 mg-33.3
Atorvastatin 80 mg-38.1

Percentage Change From Baseline in HDL-C

Blood samples taken at baseline and after 12 weeks of treatment to determine the HDL-C levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage change (Least Squares Mean)
MK-0524B 2g/20 mg26.9
MK-0524B 2g/40mg26.6
Atorvastatin 10 mg7.0
Atorvastatin 20 mg5.3
Atorvastatin 40 mg4.5
Atorvastatin 80 mg3.6

Percentage Change From Baseline in LDL-C

Blood samples taken at baseline and after 12 weeks of treatment to determine the LDL-C levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage change (Least Squares Mean)
MK-0524B 2g/20 mg-40.4
MK-0524B 2g/40mg-42.8
Atorvastatin 10 mg-33.6
Atorvastatin 20 mg-39.8
Atorvastatin 40 mg-45.6
Atorvastatin 80 mg-47.5

Percentage Change From Baseline in Lipoprotein (a) (Lp[a])

Blood samples taken at baseline and after 12 weeks of treatment to determine the Lp(a) levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage change (Median)
MK-0524B 2g/20 mg-15.2
MK-0524B 2g/40mg-14.6
Atorvastatin 10 mg0.0
Atorvastatin 20 mg0.0
Atorvastatin 40 mg7.8
Atorvastatin 80 mg8.8

Percentage Change From Baseline in Non-HDL-C

Blood samples taken at baseline and after 12 weeks of treatment to determine the non-HDL-C levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage change (Least Squares Mean)
MK-0524B 2g/20 mg-40.4
MK-0524B 2g/40mg-42.2
Atorvastatin 10 mg-31.3
Atorvastatin 20 mg-36.8
Atorvastatin 40 mg-42.6
Atorvastatin 80 mg-44.6

Percentage Change From Baseline in TC/HDL-C Ratio

Blood samples taken at baseline and after 12 weeks of treatment to determine the TC and HDL-C levels. The TC/HDL-C ratio was then calculated for baseline and Week 12 and the change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage change (Least Squares Mean)
MK-0524B 2g/20 mg-41.0
MK-0524B 2g/40mg-42.3
Atorvastatin 10 mg-28.2
Atorvastatin 20 mg-31.5
Atorvastatin 40 mg-36.0
Atorvastatin 80 mg-36.7

Percentage Change From Baseline in the LDL-C/HDL-C Ratio

Blood samples taken at baseline and after 12 weeks of treatment to determine the LDL-C and HDL-C levels. The LDL-C/HDL-C ratio was then calculated for baseline and Week 12 and the change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage Change (Least Squares Mean)
MK-0524B 2g/20 mg-50.9
MK-0524B 2g/40mg-53.0
Atorvastatin 10 mg-37.6
Atorvastatin 20 mg-42.4
Atorvastatin 40 mg-47.9
Atorvastatin 80 mg-48.8

Percentage Change From Baseline in Total Cholesterol (TC)

Blood samples taken at baseline and after 12 weeks of treatment to determine the TC levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage change (Least Squares Mean)
MK-0524B 2g/20 mg-28.1
MK-0524B 2g/40mg-30.0
Atorvastatin 10 mg-24.6
Atorvastatin 20 mg-29.4
Atorvastatin 40 mg-34.2
Atorvastatin 80 mg-36.1

Percentage Change From Baseline in Triglycerides (TG)

Blood samples taken at baseline and after 12 weeks of treatment to determine the TG levels. The change from baseline at Week 12 was recorded. (NCT00289900)
Timeframe: Baseline and Week 12

InterventionPercentage change (Median)
MK-0524B 2g/20 mg-40.3
MK-0524B 2g/40mg-42.0
Atorvastatin 10 mg-21.9
Atorvastatin 20 mg-23.8
Atorvastatin 40 mg-30.4
Atorvastatin 80 mg-33.8

Percentage of Participants Who Experience at Least 1 Clinical Adverse Event (AE)

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant. (NCT00289900)
Timeframe: up to 14 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)59.6
Atorvastatin 10, 20, 40, or 80 mg (Pooled)45.9

Percentage of Participants Who Experience at Least 1 Hepatitis-related Clinical AE

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. Hepatitis-related AEs were identified by a collective review using the following pre-specified set of preferred terms: cholestasis, hepatic necrosis, hepatocellular damage, cytolytic hepatitis, hepatitis, hepatomegaly, jaundice, hepatic failure, hepatitis cholestatic, jaundice cholestatic, hepatitis fulminant, hyperbilirubinaemia, jaundice hepatocellular, ocular icterus, yellow skin, hepatic function abnormal, acute hepatic failure, subacute hepatic failure, hepatitis acute, hepatitis toxic, hepatotoxicity, and mixed hepatocellular-cholestatic injury. (NCT00289900)
Timeframe: up to 14 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)0.0
Atorvastatin 10, 20, 40, or 80 mg (Pooled)0.1

Percentage of Participants Who Experience at Least 1 Laboratory Adverse Event (AE)

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. (NCT00289900)
Timeframe: up to 14 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)5.2
Atorvastatin 10, 20, 40, or 80 mg (Pooled)5.9

Percentage of Participants Who Were Discontinued From the Study Due to a Clinical AE

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A clinical AE was an AE reported as a result of a clinical examination or reported by the participant. Participants who were discontinued from the study due to a clinical AE were recorded. (NCT00289900)
Timeframe: up to 14 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)16.5
Atorvastatin 10, 20, 40, or 80 mg (Pooled)4.9

Percentage of Participants Who Were Discontinued From the Study Due to a Laboratory AE

An AE was defined as any unfavorable and unintended change in the structure, function, or chemistry of the body temporally associated with the use of the product, whether or not considered related to the use of the product. Any worsening (i.e., any clinically significant adverse change in frequency and/or intensity) of a preexisting condition which was temporally associated with the use of the product, was also an AE. A laboratory AE was an AE reported as a result of a laboratory assessment or test. Participants who were discontinued from the study due to a laboratory AE were recorded. (NCT00289900)
Timeframe: up to 14 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)0.7
Atorvastatin 10, 20, 40, or 80 mg (Pooled)0.7

Percentage of Participants With a Confirmed Adjudicated Cardiovascular Event

Select serious adverse cardiovascular events and all-cause mortality that occurred during the treatment phase of the study were adjudicated by an expert committee external to the sponsor. Those events confirmed by the committee a cardiovascular events were recorded. (NCT00289900)
Timeframe: up to 14 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)0.1
Atorvastatin 10, 20, 40, or 80 mg (Pooled)0.2

Percentage of Participants With CK >=10 x ULN With Muscle Symptoms

Participants had CK assessed throughout the 24 week treatment period. Participants who had any CK level that was >=10 x ULN and had associated muscle symptoms present within +/- 7 days were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)0.1
Atorvastatin 10, 20, 40, or 80 mg (Pooled)0.0

Percentage of Participants With CK >=10 x ULN With Muscle Symptoms - Drug Related

Participants had CK assessed throughout the 12 week treatment period. Participants who had any CK level that was >=10 x ULN and had associated muscle symptoms present within +/- 7 days that were reported as at least possibly related to study drug were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)0.1
Atorvastatin 10, 20, 40, or 80 mg (Pooled)0.0

Percentage of Participants With Consecutive Elevations in Alanine Aminotransferase (ALT) and/or Aspartate Aminotransferase (AST) of >=3 x Upper Limit of Normal (ULN)

Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had 2 consecutive assessments of either AST or ALT that were 3 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg and MK-0524B 2g/40mg (Pooled)0.4
Atorvastatin 10, 20, 40, or 80 mg (Pooled)1.8

Percentage of Participants With Creatine Kinase (CK) >=10 x ULN

Participants had CK assessed throughout the 12 week treatment period. Participants who had any CK level that was >=10 x ULN were recorded. The UNLs for males and females were 207 U/L and 169 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)0.1
Atorvastatin 10, 20, 40, or 80 mg (Pooled)0.1

Percentage of Participants With Elevations in ALT and/or AST of >=10 x ULN

Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of either AST or ALT that was 10 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)0.0
Atorvastatin 10, 20, 40, or 80 mg (Pooled)0.1

Percentage of Participants With Elevations in ALT and/or AST of >=5 x ULN

Participants had AST and ALT levels assessed throughout the 12 week treatment period. Participants who had an assessment of either AST or ALT that was 5 x ULN or greater were recorded. The AST UNLs for males and females were 43 U/L and 36 U/L, respectively. The ALT UNLs for males and females were 40 U/L and 33 U/L, respectively. (NCT00289900)
Timeframe: up to 12 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg and MK-0524B 2g/40mg (Pooled)0.1
Atorvastatin 10, 20, 40, or 80 mg (Pooled)0.9

Percentage of Participants With New Diagnosis of Diabetes

Participants had blood glucose levels assessed throughout the 12 week treatment period. Participants who with newly diagnosed of diabetes were recorded. A participant was classified as having new onset diabetes if they experienced an adverse Event (AE) related to a diagnosis of diabetes (based on a pre-defined set of Medical Dictionary for Regulatory Activities [MedDRA] terms), or if they started taking an anti-diabetic medication during the course of the study. The MedDRA terms were as follows: diabetes mellitus, diabetes mellitus insulin-dependent, diabetes mellitus non-insulin dependent, insulin-requiring type II diabetes mellitus, insulin resistant diabetes, diabetes with hyperosmolarity, latent autoimmune diabetes in adults. (NCT00289900)
Timeframe: up to 12 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)0.9
Atorvastatin 10, 20, 40, or 80 mg (Pooled)0.2

Percentage of Participants With New Diagnosis of Impaired Fasting Blood Glucose

Participants had blood glucose levels assessed throughout the 12 week treatment period. Participants who had the new diagnosis of impaired fasting blood glucose were recorded. A pre-defined set of MedDRA terms was used to identify participants whose glycemic status became 'impaired' during the course of treatment (from clinical adverse experience reports). The MedDRA terms were as follows: blood glucose increased, blood glucose abnormal, glucose tolerance decreased, glucose tolerance test abnormal, carbohydrate tolerance decreased, glucose tolerance impaired, hyperglycaemia, impaired fasting glucose, impaired insulin secretion, metabolic syndrome, insulin resistance, insulin resistance syndrome. (NCT00289900)
Timeframe: up to 12 weeks

InterventionPercentage of Participants (Number)
MK-0524B 2g/20 mg or MK-0524B 2g/40mg (Pooled)0.2
Atorvastatin 10, 20, 40, or 80 mg (Pooled)0.1

Change in Proteinuria

(NCT00108485)
Timeframe: Baseline, 1 year

Interventionmg/dL (Number)
Extended Release Niacin42
Placebo63

Incidents of Rhabdomyolysis

(NCT00203476)
Timeframe: 12 weeks

Interventionparticipants (Number)
Niacin0
Colestipol0
Ezetimibe0

LDL Goal Attainment

Each participant had his LDL goal calculated based on the NCEP ATPIII guidelines. (NCT00203476)
Timeframe: 12 weeks

Interventionparticipants (Number)
Niacin6
Colestipol6
Ezetimibe9

LFT Elevation

(NCT00203476)
Timeframe: 12 weeks

Interventionparticipants (Number)
Niacin1
Colestipol1
Ezetimibe2

Change in HDL From Baseline to 12 Weeks.

(NCT00203476)
Timeframe: baseline and 12 weeks

,,
Interventionmg/dl (Mean)
baseline12 weeks
Colestipol39.2237.56
Ezetimibe32.9034.70
Niacin42.3343.00

Reviews

119 reviews available for niacin and Hyperlipemia

ArticleYear
Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease.
    Cardiovascular drugs and therapy, 2021, Volume: 35, Issue:3

    Topics: Atherosclerosis; Ezetimibe; Fibric Acids; Glomerular Filtration Rate; Humans; Hydroxymethylglutaryl-

2021
Controversies on HDL: should it be a target biomarker in patients with lipid disorders?
    Current vascular pharmacology, 2014, Volume: 12, Issue:4

    Topics: Apolipoprotein A-I; Biomarkers; Cardiovascular Diseases; Cholesterol Ester Transfer Proteins; Choles

2014
Lipid-lowering therapies, glucose control and incident diabetes: evidence, mechanisms and clinical implications.
    Cardiovascular drugs and therapy, 2014, Volume: 28, Issue:4

    Topics: Animals; Azetidines; Bile Acids and Salts; Blood Glucose; Cholesterol Ester Transfer Proteins; Diabe

2014
Revising the high-density lipoprotein targeting strategies - insights from human and preclinical studies.
    Critical reviews in clinical laboratory sciences, 2014, Volume: 51, Issue:6

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Fibric Acids; Humans; Hyperlipidemias; Hypolipidemic Agen

2014
Niacin in the Treatment of Hyperlipidemias in Light of New Clinical Trials: Has Niacin Lost its Place?
    Medical science monitor : international medical journal of experimental and clinical research, 2015, Jul-25, Volume: 21

    Topics: Animals; Cardiovascular Diseases; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Factor

2015
Pharmacological Effects of Niacin on Acute Hyperlipemia.
    Current medicinal chemistry, 2016, Volume: 23, Issue:25

    Topics: Adenylyl Cyclases; Cholesterol, HDL; Cholesterol, LDL; Cyclooxygenase 1; Cyclooxygenase 2; Humans; H

2016
Pleiotropic effects of niacin: Current possibilities for its clinical use.
    Acta pharmaceutica (Zagreb, Croatia), 2016, Dec-01, Volume: 66, Issue:4

    Topics: Animals; Anti-Inflammatory Agents, Non-Steroidal; Antioxidants; Atherosclerosis; Disease Progression

2016
Lipid lowering treatment patterns and goal attainment in Nordic patients with hyperlipidemia.
    Scandinavian cardiovascular journal : SCJ, 2008, Volume: 42, Issue:4

    Topics: Cholesterol; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Humans; Hydroxymethylglu

2008
LDL reduction: how low should we go and is it safe?
    Current cardiology reports, 2008, Volume: 10, Issue:6

    Topics: Allylamine; Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Colesevelam Hydrochloride; Coron

2008
A review of trials evaluating nonstatin lipid-lowering therapies.
    Current atherosclerosis reports, 2009, Volume: 11, Issue:1

    Topics: Anticholesteremic Agents; Azetidines; Clinical Trials as Topic; Drug Therapy, Combination; Ezetimibe

2009
Expert perspective: reducing cardiovascular risk in metabolic syndrome and type 2 diabetes mellitus beyond low-density lipoprotein cholesterol lowering.
    The American journal of cardiology, 2008, Dec-22, Volume: 102, Issue:12A

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, LDL; Diabetes Mellitus, Type 2; Drug

2008
Lipid metabolism and hyperlipidemia in dogs.
    Veterinary journal (London, England : 1997), 2010, Volume: 183, Issue:1

    Topics: Animals; Diet, Reducing; Dog Diseases; Dogs; Fatty Acids, Omega-3; Hyperlipidemias; Hypertriglycerid

2010
Lowering low-density lipoprotein cholesterol: statins, ezetimibe, bile acid sequestrants, and combinations: comparative efficacy and safety.
    Endocrinology and metabolism clinics of North America, 2009, Volume: 38, Issue:1

    Topics: Animals; Anticholesteremic Agents; Azetidines; Bile Acids and Salts; Cholesterol, LDL; Drug Therapy,

2009
Second line options for hyperlipidemia management after cardiac transplantation.
    Cardiovascular therapeutics, 2013, Volume: 31, Issue:3

    Topics: Azetidines; Bezafibrate; Diet; Exercise; Ezetimibe; Fish Oils; Heart Transplantation; Humans; Hydrox

2013
Nicotinic acid as a lipid-modifying drug--a review.
    Atherosclerosis. Supplements, 2013, Volume: 14, Issue:1

    Topics: Animals; Biomarkers; Chemistry, Pharmaceutical; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipid

2013
Understanding niacin formulations.
    The American journal of managed care, 2002, Volume: 8, Issue:12 Suppl

    Topics: Chemistry, Pharmaceutical; Clinical Trials as Topic; Humans; Hyperlipidemias; Hypolipidemic Agents;

2002
Niacin-based therapy for dyslipidemia: past evidence and future advances.
    The American journal of managed care, 2002, Volume: 8, Issue:12 Suppl

    Topics: Adult; Anticholesteremic Agents; Cholesterol, HDL; Drug Therapy, Combination; Female; Humans; Hyperl

2002
Treatment of dyslipidaemia in high-risk patients: too little, too late.
    International journal of clinical practice. Supplement, 2002, Issue:130

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combin

2002
Management of hypercholesterolaemia in the patient with diabetes.
    International journal of clinical practice. Supplement, 2002, Issue:130

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Diabetes Mellitus, T

2002
Current drug treatments for lipid management.
    Managed care (Langhorne, Pa.), 2002, Volume: 11, Issue:9 Suppl

    Topics: Bile Acids and Salts; Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Clofibric Acid;

2002
Combination therapy for combined dyslipidemia.
    The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fatty

2002
Niacin extended-release/lovastatin: combination therapy for lipid disorders.
    Expert opinion on pharmacotherapy, 2002, Volume: 3, Issue:12

    Topics: Clinical Trials as Topic; Delayed-Action Preparations; Drug Combinations; Humans; Hyperlipidemias; H

2002
Management of dyslipidemia in the high-risk patient.
    American heart journal, 2002, Volume: 144, Issue:6 Suppl

    Topics: Anticholesteremic Agents; Cholesterol, LDL; Delayed-Action Preparations; Drug Therapy, Combination;

2002
Niacin-ER and lovastatin treatment of hypercholesterolemia and mixed dyslipidemia.
    The Annals of pharmacotherapy, 2003, Volume: 37, Issue:1

    Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Delayed-Action Preparations; Drug Comb

2003
Therapy to reduce risk of coronary heart disease.
    Clinical cardiology, 2003, Volume: 26, Issue:1

    Topics: Anion Exchange Resins; Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Humans;

2003
What future for combination therapies?
    International journal of clinical practice. Supplement, 2003, Issue:134

    Topics: Bile Acids and Salts; Clofibric Acid; Drug Therapy, Combination; Fish Oils; Forecasting; Humans; Hyp

2003
Therapeutic approaches to dyslipidemia in diabetes mellitus and metabolic syndrome.
    Current opinion in cardiology, 2003, Volume: 18, Issue:4

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Diabetes Mellitus, Type 2; Diabetic Angiopat

2003
Toxicity of antilipidemic agents: facts and fictions.
    Current atherosclerosis reports, 2003, Volume: 5, Issue:5

    Topics: Chemical and Drug Induced Liver Injury; Drug Interactions; Drug Therapy, Combination; Humans; Hydrox

2003
Niacin: a powerful adjunct to other lipid-lowering drugs in reducing plaque progression and acute coronary events.
    Current atherosclerosis reports, 2003, Volume: 5, Issue:5

    Topics: Acute Disease; Algorithms; Clinical Trials as Topic; Coronary Artery Disease; Coronary Disease; Diab

2003
Niacin as a component of combination therapy for dyslipidemia.
    Mayo Clinic proceedings, 2003, Volume: 78, Issue:6

    Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Coronary Disease; Delayed-Action Prepa

2003
Lipoprotein distribution in the metabolic syndrome, type 2 diabetes mellitus, and familial combined hyperlipidemia.
    The American journal of cardiology, 2003, Aug-18, Volume: 92, Issue:4A

    Topics: Abdomen; Adipose Tissue; Diabetes Mellitus, Type 2; Humans; Hydroxymethylglutaryl-CoA Reductase Inhi

2003
[MECHANISM OF ACTION OF LIPEMIA-CLEARING PREPARATIONS].
    [Sogo rinsho] Clinic all-round, 1963, Volume: 12

    Topics: Dextrans; Edetic Acid; Heparin; Hyperlipidemias; Lipoprotein Lipase; Neomycin; Niacin; Nicotinic Aci

1963
What's new in lipid management?
    Pharmacotherapy, 2003, Volume: 23, Issue:9 Pt 2

    Topics: Bile Acids and Salts; Clinical Trials as Topic; Drug Therapy, Combination; Humans; Hydroxymethylglut

2003
Antiatherothrombotic effects of nicotinic acid.
    Atherosclerosis, 2003, Volume: 171, Issue:1

    Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Fibrinolytic Agents; Humans; Hydroxymethylglut

2003
The metabolic syndrome: pathophysiology, clinical relevance, and use of niacin.
    The Annals of pharmacotherapy, 2004, Volume: 38, Issue:2

    Topics: Adult; Aged; Cholesterol; Coronary Disease; Cost-Benefit Analysis; Female; Humans; Hyperlipidemias;

2004
The effect of fibrates and other lipid-lowering drugs on plasma homocysteine levels.
    Expert opinion on drug safety, 2004, Volume: 3, Issue:2

    Topics: Fenofibrate; Homocysteine; Humans; Hyperhomocysteinemia; Hyperlipidemias; Hypolipidemic Agents; Niac

2004
Dyslipidemia treatment: current considerations and unmet needs.
    Expert review of cardiovascular therapy, 2003, Volume: 1, Issue:1

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Clinical Trials as Topic; Drug Therapy, Combination;

2003
New perspectives on the use of niacin in the treatment of lipid disorders.
    Archives of internal medicine, 2004, Apr-12, Volume: 164, Issue:7

    Topics: Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Dose-Response Relationship, Drug; D

2004
Combination therapy for the treatment of dyslipidemia.
    Current opinion in investigational drugs (London, England : 2000), 2004, Volume: 5, Issue:3

    Topics: Drug Therapy, Combination; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias;

2004
Extended-release niacin for modifying the lipoprotein profile.
    Expert opinion on pharmacotherapy, 2004, Volume: 5, Issue:6

    Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Delayed-Action Preparations; Humans; H

2004
A meta-analysis of randomized controlled studies on the effects of extended-release niacin in women.
    The American journal of cardiology, 2004, Jul-01, Volume: 94, Issue:1

    Topics: Adult; Aged; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations; Double-Blind Method; F

2004
Combination therapy in the management of complex dyslipidemias.
    Current opinion in lipidology, 2004, Volume: 15, Issue:4

    Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cardiovascular Diseases; Drug Therapy, Combination

2004
Treating low HDL--from bench to bedside.
    Clinical biochemistry, 2004, Volume: 37, Issue:8

    Topics: Animals; Cholesterol; Coronary Artery Disease; Coronary Disease; Endothelium, Vascular; Humans; Hype

2004
Niaspan, the prolonged release preparation of nicotinic acid (niacin), the broad-spectrum lipid drug.
    International journal of clinical practice, 2004, Volume: 58, Issue:7

    Topics: Arteriosclerosis; Delayed-Action Preparations; Double-Blind Method; Fatty Acids, Nonesterified; Fema

2004
Significance of high density lipoprotein-cholesterol in cardiovascular risk prevention: recommendations of the HDL Forum.
    American journal of cardiovascular drugs : drugs, devices, and other interventions, 2004, Volume: 4, Issue:5

    Topics: Bezafibrate; Cardiovascular Diseases; Cholesterol; Cholesterol, HDL; Fenofibrate; Gemfibrozil; Human

2004
The emerging role of lipoproteins in atherogenesis: beyond LDL cholesterol.
    Seminars in vascular medicine, 2004, Volume: 4, Issue:2

    Topics: Animals; Arteriosclerosis; Carrier Proteins; Cholesterol Ester Transfer Proteins; Cholesterol, HDL;

2004
Addressing cardiovascular risk beyond low-density lipoprotein cholesterol: the high-density lipoprotein cholesterol story.
    Current cardiology reports, 2004, Volume: 6, Issue:6

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination; Humans; Hydr

2004
The effects of niacin on lipoprotein subclass distribution.
    Preventive cardiology, 2004,Fall, Volume: 7, Issue:4

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Humans; Hyperlipidemias; Niacin

2004
[Low HDL-cholesterol, high triglycerides--well known but often ignored].
    Praxis, 2004, Nov-10, Volume: 93, Issue:46

    Topics: Adult; Aged; Anticholesteremic Agents; Arteriosclerosis; Atorvastatin; Cholesterol, HDL; Clofibric A

2004
Clinical update on the use of niacin for the treatment of dyslipidemia.
    Journal of the American Academy of Nurse Practitioners, 2004, Volume: 16, Issue:12

    Topics: Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Practice Guidelines as Topic; Safety; Treatme

2004
Effect of lipid-lowering drug therapy on small-dense low-density lipoprotein.
    The Annals of pharmacotherapy, 2005, Volume: 39, Issue:3

    Topics: Cholesterol, LDL; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipid

2005
Rationale for combination therapy with statin drugs in the treatment of dyslipidemia.
    Current atherosclerosis reports, 2005, Volume: 7, Issue:1

    Topics: Anion Exchange Resins; Antihypertensive Agents; Azetidines; Benzenesulfonates; Clofibric Acid; Drug

2005
[Dyslipidemia management in patients with impaired glucose tolerance].
    Nihon rinsho. Japanese journal of clinical medicine, 2005, Volume: 63 Suppl 2

    Topics: Anticholesteremic Agents; Arteriosclerosis; Cholesterol; Cholesterol, HDL; Clofibric Acid; Eicosapen

2005
Update on risk factors for atherosclerosis: the role of inflammation and apolipoprotein E.
    Medsurg nursing : official journal of the Academy of Medical-Surgical Nurses, 2005, Volume: 14, Issue:1

    Topics: Apolipoproteins E; Arteriosclerosis; Cholestyramine Resin; Diet, Fat-Restricted; Exercise; Genotype;

2005
[Niacin--an additive therapeutic approach for optimizing lipid profile].
    Medizinische Klinik (Munich, Germany : 1983), 2005, Apr-15, Volume: 100, Issue:4

    Topics: Cholesterol; Cholesterol, HDL; Controlled Clinical Trials as Topic; Coronary Disease; Drug Therapy,

2005
Commentary: A new approach to atherogenic dyslipidemia.
    Postgraduate medicine, 2005, Volume: 117, Issue:4

    Topics: Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Humans; Hyperlipidemias; Hypolipidemic

2005
Cholesterol lowering in diabetes. New evidence supports aggressive LDL-C targets.
    Postgraduate medicine, 2005, Volume: 117, Issue:4

    Topics: Cholesterol, LDL; Coronary Disease; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hyperlipid

2005
Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel.
    Current medical research and opinion, 2005, Volume: 21, Issue:5

    Topics: Cardiovascular Diseases; Diabetes Mellitus, Type 2; Europe; Humans; Hyperlipidemias; Hypolipidemic A

2005
Nicotinic acid: the broad-spectrum lipid drug. A 50th anniversary review.
    Journal of internal medicine, 2005, Volume: 258, Issue:2

    Topics: Adipose Tissue; Arteriosclerosis; Coronary Disease; Fatty Acids, Nonesterified; Fibrinolysis; Flushi

2005
Management of dyslipidemia in patients with complicated metabolic syndrome.
    The American journal of cardiology, 2005, Aug-22, Volume: 96, Issue:4A

    Topics: Clofibric Acid; Fatty Liver; HIV-Associated Lipodystrophy Syndrome; Humans; Hydroxymethylglutaryl-Co

2005
Beyond LDL-cholesterol: HDL-cholesterol as a target for atherosclerosis prevention.
    Experimental and clinical endocrinology & diabetes : official journal, German Society of Endocrinology [and] German Diabetes Association, 2005, Volume: 113, Issue:8

    Topics: Arteries; Atherosclerosis; Cholesterol, HDL; Cholesterol, LDL; Drug Evaluation; Humans; Hyperlipidem

2005
Management of hyperlipidemia: new LDL-C targets for persons at high-risk for cardiovascular events.
    Medical science monitor : international medical journal of experimental and clinical research, 2006, Volume: 12, Issue:2

    Topics: Azetidines; Cardiovascular Diseases; Cholesterol, LDL; Cholestyramine Resin; Clofibric Acid; Drug Th

2006
[Nicotinic acid: an unjustly neglected remedy].
    Casopis lekaru ceskych, 2006, Volume: 145, Issue:11

    Topics: Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin

2006
[Influence of combined, hypolipemic therapy on lipids and non-lipid atherosclerosis risk factors].
    Polski merkuriusz lekarski : organ Polskiego Towarzystwa Lekarskiego, 2007, Volume: 22, Issue:127

    Topics: Anticholesteremic Agents; Atherosclerosis; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric

2007
[Niacin in therapy].
    Postepy higieny i medycyny doswiadczalnej (Online), 2007, May-15, Volume: 61

    Topics: Adipocytes; Adiponectin; Animals; Cholesterol, HDL; Delayed-Action Preparations; Flushing; Humans; H

2007
Present-day uses of niacin: effects on lipid and non-lipid parameters.
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:11

    Topics: Animals; Cholesterol, HDL; Cholesterol, LDL; Humans; Hyperlipidemias; Lipids; Metabolic Syndrome; Ni

2007
Nicotinic acid: pharmacological effects and mechanisms of action.
    Annual review of pharmacology and toxicology, 2008, Volume: 48

    Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Clinical Trials as Topic; Humans; Hyperlipidemias

2008
Do we need a statin-nicotinic acid-aspirin mini-polypill to treat combined hyperlipidaemia?
    Expert opinion on pharmacotherapy, 2007, Volume: 8, Issue:14

    Topics: Aspirin; Drug Combinations; Dyslipidemias; Health Services Needs and Demand; Humans; Hydroxymethylgl

2007
FPIN's clinical inquiries. Best alternatives to statins for treating hyperlipidemia.
    American family physician, 2007, Oct-01, Volume: 76, Issue:7

    Topics: Anion Exchange Resins; Azetidines; Clofibric Acid; Evidence-Based Medicine; Ezetimibe; Fatty Acids,

2007
Nicotinic acid in the treatment of hyperlipidaemia.
    Fundamental & clinical pharmacology, 2007, Volume: 21 Suppl 2

    Topics: Cholesterol, HDL; Clinical Trials as Topic; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin

2007
Management of hyperlipidemia with statins in the older patient.
    Clinical interventions in aging, 2006, Volume: 1, Issue:4

    Topics: Aged; Anticholesteremic Agents; Cholesterol, LDL; Clofibric Acid; Humans; Hydroxymethylglutaryl-CoA

2006
Comprehensive lipid management versus aggressive low-density lipoprotein lowering to reduce cardiovascular risk.
    The American journal of cardiology, 2008, Apr-17, Volume: 101, Issue:8A

    Topics: Anticholesteremic Agents; Apolipoprotein A-I; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol

2008
Nicotinic acid, alone and in combinations, for reduction of cardiovascular risk.
    The American journal of cardiology, 2008, Apr-17, Volume: 101, Issue:8A

    Topics: Anticholesteremic Agents; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Clofibric Aci

2008
Recommendations for treatment of hyperlipidemia in adults. A joint statement of the Nutrition Committee and the Council on Arteriosclerosis.
    Circulation, 1984, Volume: 69, Issue:5

    Topics: Cholesterol; Clofibrate; Coronary Disease; Female; Gemfibrozil; Humans; Hypercholesterolemia; Hyperl

1984
Therapy of hyperlipidemic states.
    Annual review of medicine, 1982, Volume: 33

    Topics: Cholesterol, Dietary; Cholestyramine Resin; Clofibrate; Colestipol; Dietary Fats; Drug Therapy, Comb

1982
Niacin for lipid disorders. Indications, effectiveness, and safety.
    Postgraduate medicine, 1995, Volume: 98, Issue:2

    Topics: Contraindications; Drug Eruptions; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Liver; Mal

1995
Hyperlipidemia: perspectives in diagnosis and treatment.
    Southern medical journal, 1995, Volume: 88, Issue:4

    Topics: Cholesterol, HDL; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Coronary Disease; Diet, Fat-Re

1995
Niacin-induced myopathy.
    The American journal of cardiology, 1994, Oct-15, Volume: 74, Issue:8

    Topics: Aged; Aged, 80 and over; Female; Humans; Hyperlipidemias; Male; Muscular Diseases; Niacin

1994
Niacin: a therapeutic dilemma. "One man's drink is another's poison".
    The American journal of medicine, 1994, Volume: 97, Issue:4

    Topics: Delayed-Action Preparations; Humans; Hyperlipidemias; Niacin

1994
Dyslipidemia and coronary artery disease.
    Clinical cardiology, 1994, Volume: 17, Issue:10

    Topics: Arteriosclerosis; Cholesterol; Coronary Disease; Drug Therapy, Combination; Exercise; Gemfibrozil; H

1994
Number-needed-to-treat analysis of the prevention of myocardial infarction and death by antidyslipidemic therapy.
    The Journal of family practice, 1996, Volume: 42, Issue:6

    Topics: Coronary Angiography; Coronary Artery Disease; Disease Progression; Female; Humans; Hydroxymethylglu

1996
Trials of the effects of drugs and hormones on lipids and lipoproteins.
    Current opinion in lipidology, 1995, Volume: 6, Issue:6

    Topics: Clinical Trials as Topic; Estrogen Replacement Therapy; Female; Hormones; Human Growth Hormone; Huma

1995
New developments in the use of niacin for treatment of hyperlipidemia: new considerations in the use of an old drug.
    Coronary artery disease, 1996, Volume: 7, Issue:4

    Topics: Apolipoprotein B-100; Apolipoproteins B; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Follow-Up

1996
Lipid management: current diet and drug treatment options.
    The American journal of medicine, 1996, Oct-08, Volume: 101, Issue:4A

    Topics: Diet; Gemfibrozil; Humans; Hyperlipidemias; Niacin; Patient Education as Topic

1996
Choosing the right lipid-regulating agent. A guide to selection.
    Drugs, 1996, Volume: 52, Issue:5

    Topics: Anticholesteremic Agents; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Fenofibrat

1996
[The role of nicotinic acid in the treatment of atherosclerosis and atherogenic dyslipidemia].
    Klinicheskaia meditsina, 1996, Volume: 74, Issue:9

    Topics: Arteriosclerosis; Humans; Hyperlipidemias; Lipids; Niacin; Treatment Outcome

1996
Perspectives in the treatment of dyslipidemias in the prevention of coronary heart disease.
    Angiology, 1998, Volume: 49, Issue:5

    Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Combined Modality Therapy; Coronary Artery Disease;

1998
Lack of predictability of classical animal models for hypolipidemic activity: a good time for mice?
    Atherosclerosis, 1998, Volume: 140, Issue:1

    Topics: Animals; Disease Models, Animal; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipide

1998
Clinical profiles of plain versus sustained-release niacin (Niaspan) and the physiologic rationale for nighttime dosing.
    The American journal of cardiology, 1998, Dec-17, Volume: 82, Issue:12A

    Topics: Circadian Rhythm; Delayed-Action Preparations; Drug Administration Schedule; Humans; Hyperlipidemias

1998
Treatment of hyperlipidemia with combined niacin-statin regimens.
    The American journal of cardiology, 1998, Dec-17, Volume: 82, Issue:12A

    Topics: Anticholesteremic Agents; Clinical Trials as Topic; Delayed-Action Preparations; Drug Therapy, Combi

1998
Drug treatment of lipid disorders.
    The New England journal of medicine, 1999, Aug-12, Volume: 341, Issue:7

    Topics: Anion Exchange Resins; Cardiovascular Diseases; Clofibrate; Female; Humans; Hydroxymethylglutaryl-Co

1999
Pharmacology department: pharmacologic approaches to abnormal blood lipids.
    The Journal of cardiovascular nursing, 2000, Volume: 14, Issue:2

    Topics: Anion Exchange Resins; Antioxidants; Fenofibrate; Gemfibrozil; Humans; Hydroxymethylglutaryl-CoA Red

2000
Combination drug therapy for combined hyperlipidemia.
    Current cardiology reports, 1999, Volume: 1, Issue:3

    Topics: Arteriosclerosis; Drug Therapy, Combination; Fish Oils; Humans; Hyperlipidemias; Hypolipidemic Agent

1999
Novel lipid-regulating drugs.
    Expert opinion on investigational drugs, 2000, Volume: 9, Issue:11

    Topics: Animals; Anticholesteremic Agents; Bile Acids and Salts; Carrier Proteins; Cholesterol Ester Transfe

2000
Combination drug therapy for dyslipidemia.
    Current atherosclerosis reports, 1999, Volume: 1, Issue:1

    Topics: Anion Exchange Resins; Cholesterol, LDL; Drug Therapy, Combination; Fish Oils; Humans; Hydroxymethyl

1999
Use of niacin in the prevention and management of hyperlipidemia.
    Progress in cardiovascular nursing, 2001,Winter, Volume: 16, Issue:1

    Topics: Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Drug Monitoring; Humans; Hyperlipidemias; Liver Fun

2001
[Drug combination therapies for patients with hyperlipidemia and its significance].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3

    Topics: Anion Exchange Resins; Bezafibrate; Cholesterol, LDL; Cost-Benefit Analysis; Drug Therapy, Combinati

2001
[Nicotinic acid and the derivative].
    Nihon rinsho. Japanese journal of clinical medicine, 2001, Volume: 59 Suppl 3

    Topics: Anticholesteremic Agents; Clinical Trials as Topic; Coronary Disease; Drug Therapy, Combination; Hum

2001
Dyslipidemia, gender, and the role of high-density lipoprotein cholesterol: implications for therapy.
    The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A

    Topics: Adult; Aging; Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipidemias; Male; Menopause;

2000
Divergent approaches to the treatment of dyslipidemia with low levels of high-density lipoprotein cholesterol.
    The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A

    Topics: Cholesterol, HDL; Clinical Trials as Topic; Drug Combinations; Ethanol; Gemfibrozil; Humans; Hydroxy

2000
Clinical treatment of dyslipidemia: practice patterns and missed opportunities.
    The American journal of cardiology, 2000, Dec-21, Volume: 86, Issue:12A

    Topics: Age Distribution; Aged; Coronary Disease; Female; Humans; Hyperlipidemias; Male; Medical Records Sys

2000
Treating mixed dyslipidemias: why and how.
    Clinical cardiology, 2001, Volume: 24, Issue:7 Suppl

    Topics: Cholesterol, HDL; Cholesterol, LDL; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlip

2001
Combination lipid-altering therapy: an emerging treatment paradigm for the 21st century.
    Current atherosclerosis reports, 2001, Volume: 3, Issue:5

    Topics: Coronary Disease; Drug Interactions; Drug Therapy, Combination; Humans; Hypercholesterolemia; Hyperl

2001
Pathophysiology and treatment of the dyslipidemia of insulin resistance.
    Current cardiology reports, 2001, Volume: 3, Issue:5

    Topics: Cardiovascular Diseases; Enzyme Inhibitors; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors;

2001
Managing dyslipidemia in the high-risk patient.
    The American journal of cardiology, 2002, Mar-07, Volume: 89, Issue:5A

    Topics: Adult; Anticholesteremic Agents; Atorvastatin; Bile Acids and Salts; Cholesterol, LDL; Clinical Tria

2002
Should pediatric patients with hyperlipidemia receive drug therapy?
    Paediatric drugs, 2002, Volume: 4, Issue:4

    Topics: Anticholesteremic Agents; Child; Cholestyramine Resin; Coronary Disease; Fatty Acids, Omega-3; Human

2002
Drug therapy of hyperlipidemia.
    Current problems in cardiology, 1992, Volume: 17, Issue:9

    Topics: Anticholesteremic Agents; Butyrates; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination;

1992
Cholesterol-lowering drugs as cardioprotective agents.
    The American journal of cardiology, 1992, Dec-21, Volume: 70, Issue:21

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA

1992
Effects of various lipid-lowering treatments in diabetics.
    Journal of cardiovascular pharmacology, 1990, Volume: 16 Suppl 9

    Topics: Clofibrate; Diabetes Complications; Diabetes Mellitus; Humans; Hydroxymethylglutaryl-CoA Reductase I

1990
Use of niacin as a drug.
    Annual review of nutrition, 1991, Volume: 11

    Topics: Animals; Humans; Hyperlipidemias; Lipoproteins, VLDL; Liver; Niacin; Niacinamide; Structure-Activity

1991
Management of hyperlipidemia of kidney disease.
    Kidney international, 1990, Volume: 37, Issue:3

    Topics: Anticholesteremic Agents; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hypercholesterolem

1990
Drug therapy in dyslipidemia.
    Scandinavian journal of clinical and laboratory investigation. Supplementum, 1990, Volume: 199

    Topics: Anticholesteremic Agents; Bile Acids and Salts; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA

1990
Nicotinic acid: a review of its clinical use in the treatment of lipid disorders.
    Pharmacotherapy, 1988, Volume: 8, Issue:5

    Topics: Humans; Hyperlipidemias; Niacin

1988
When to treat hyperlipidemia.
    Advances in internal medicine, 1988, Volume: 33

    Topics: Animals; Arteriosclerosis; Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Gemfibrozil; H

1988
Reducing cardiac deaths with hypolipidemic drugs.
    Postgraduate medicine, 1987, Nov-01, Volume: 82, Issue:6

    Topics: Cholesterol; Cholestyramine Resin; Clofibrate; Colestipol; Coronary Disease; Feeding Behavior; Gemfi

1987
Contemporary recommendations for evaluating and treating hyperlipidemia.
    Clinical pharmacy, 1986, Volume: 5, Issue:2

    Topics: Clofibrate; Dextrothyroxine; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Lip

1986
The diagnosis and management of hyperlipidemia.
    Disease-a-month : DM, 1986, Volume: 32, Issue:5

    Topics: Adolescent; Adult; Child; Child, Preschool; Cholesterol; Cholestyramine Resin; Chylomicrons; Clofibr

1986
Pharmacological modification of lipoprotein metabolism.
    Biochemical Society transactions, 1987, Volume: 15, Issue:2

    Topics: Animals; Bile Acids and Salts; Cholestyramine Resin; Clofibrate; Colestipol; Humans; Hydroxymethylgl

1987
Antihyperlipidemic properties of beta-pyridylcarbinol. A review of preclinical studies.
    Life sciences, 1985, Nov-25, Volume: 37, Issue:21

    Topics: Adipose Tissue; Adrenal Cortex; Animals; Blood Glucose; Cholesterol; Cholesterol, Dietary; Coronary

1985

Trials

46 trials available for niacin and Hyperlipemia

ArticleYear
Plasma Lipidome Analysis by Liquid Chromatography-High Resolution Mass Spectrometry and Ion Mobility of Hypertriglyceridemic Patients on Extended-Release Nicotinic Acid: a Pilot Study.
    Cardiovascular drugs and therapy, 2017, Volume: 31, Issue:3

    Topics: Adult; Cholesterol, HDL; Chromatography, Liquid; Cross-Over Studies; Delayed-Action Preparations; Do

2017
Impaired lipoprotein processing in HIV patients on antiretroviral therapy: aberrant high-density lipoprotein lipids, stability, and function.
    Arteriosclerosis, thrombosis, and vascular biology, 2013, Volume: 33, Issue:7

    Topics: Anti-Retroviral Agents; Biomarkers; Cell Line, Tumor; Cholesterol Esters; Combined Modality Therapy;

2013
Changes in lipoprotein particle number with ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidemic patients.
    Journal of the American Heart Association, 2013, Aug-07, Volume: 2, Issue:4

    Topics: Aged; Azetidines; Biomarkers; Delayed-Action Preparations; Double-Blind Method; Drug Combinations; D

2013
Effects of extended-release niacin/laropiprant on correlations between apolipoprotein B, LDL-cholesterol and non-HDL-cholesterol in patients with type 2 diabetes.
    Lipids in health and disease, 2016, Jul-12, Volume: 15, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Apolipoprotein B-100; Blood Glucose; Cholesterol, HDL; Cholesterol,

2016
Extended-release niacin alters the metabolism of plasma apolipoprotein (Apo) A-I and ApoB-containing lipoproteins.
    Arteriosclerosis, thrombosis, and vascular biology, 2008, Volume: 28, Issue:9

    Topics: Adult; Aged; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoprotein B-100; Apolipoprotein B-48; Cho

2008
Long-term safety and efficacy of triple combination ezetimibe/simvastatin plus extended-release niacin in patients with hyperlipidemia.
    The American journal of cardiology, 2010, Feb-15, Volume: 105, Issue:4

    Topics: Adolescent; Adult; Aged; Azetidines; Biomarkers; C-Reactive Protein; Cholesterol, HDL; Cholesterol,

2010
Long-term efficacy and safety of ezetimibe/simvastatin coadministered with extended-release niacin in hyperlipidaemic patients with diabetes or metabolic syndrome.
    Diabetes, obesity & metabolism, 2010, Volume: 12, Issue:11

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Delayed-Action Preparations; Diabetes Mellit

2010
Combination of niacin extended-release and simvastatin results in a less atherogenic lipid profile than atorvastatin monotherapy.
    Vascular health and risk management, 2010, Nov-24, Volume: 6

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Atherosclerosis; Atorvastatin; Delayed-Act

2010
Lipid-altering efficacy and safety profile of co-administered extended release niacin/laropiprant and simvastatin versus atorvastatin in patients with mixed hyperlipidemia.
    International journal of cardiology, 2013, Jul-15, Volume: 167, Issue:1

    Topics: Adult; Aged; Atorvastatin; Delayed-Action Preparations; Double-Blind Method; Drug Therapy, Combinati

2013
Effect of extended-release niacin on new-onset diabetes among hyperlipidemic patients treated with ezetimibe/simvastatin in a randomized controlled trial.
    Diabetes care, 2012, Volume: 35, Issue:4

    Topics: Adolescent; Adult; Age of Onset; Aged; Azetidines; Delayed-Action Preparations; Diabetes Complicatio

2012
Efficacy, safety, and tolerability of once-daily niacin for the treatment of dyslipidemia associated with type 2 diabetes: results of the assessment of diabetes control and evaluation of the efficacy of niaspan trial.
    Archives of internal medicine, 2002, Jul-22, Volume: 162, Issue:14

    Topics: Adult; Aged; Biomarkers; Blood Glucose; Body Mass Index; C-Reactive Protein; Cholesterol, HDL; Chole

2002
Comparison of once-daily, niacin extended-release/lovastatin with standard doses of atorvastatin and simvastatin (the ADvicor Versus Other Cholesterol-Modulating Agents Trial Evaluation [ADVOCATE]).
    The American journal of cardiology, 2003, Mar-15, Volume: 91, Issue:6

    Topics: Adolescent; Adult; Aged; Anticholesteremic Agents; Atorvastatin; Delayed-Action Preparations; Dose-R

2003
A dose-ranging study of a new, once-daily, dual-component drug product containing niacin extended-release and lovastatin.
    Clinical cardiology, 2003, Volume: 26, Issue:3

    Topics: Analysis of Variance; Chi-Square Distribution; Delayed-Action Preparations; Dose-Response Relationsh

2003
Beneficial effects of rosuvastatin alone and in combination with extended-release niacin in patients with a combined hyperlipidemia and low high-density lipoprotein cholesterol levels.
    The American journal of cardiology, 2003, Jun-01, Volume: 91, Issue:11

    Topics: Adolescent; Adult; Cholesterol, HDL; Creatine Kinase; Delayed-Action Preparations; Dose-Response Rel

2003
[Comparative efficiency of prolonged diet and drug therapies for hyperlipidemias in patients with ischemic heart disease].
    Klinicheskaia meditsina, 2004, Volume: 82, Issue:5

    Topics: Aged; Bezafibrate; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Mi

2004
Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.
    The American journal of cardiology, 2004, Aug-01, Volume: 94, Issue:3

    Topics: Administration, Oral; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Administra

2004
Niacin in HIV-infected individuals with hyperlipidemia receiving potent antiretroviral therapy.
    Clinical infectious diseases : an official publication of the Infectious Diseases Society of America, 2004, Aug-01, Volume: 39, Issue:3

    Topics: Antiretroviral Therapy, Highly Active; Cholesterol; Delayed-Action Preparations; Glucose Tolerance T

2004
Rosuvastatin alone or with extended-release niacin: a new therapeutic option for patients with combined hyperlipidemia.
    Preventive cardiology, 2004,Fall, Volume: 7, Issue:4

    Topics: Adult; Apolipoproteins; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Delayed-Action Preparations

2004
Effects of combined dietary supplementation on oxidative and inflammatory status in dyslipidemic subjects.
    Nutrition, metabolism, and cardiovascular diseases : NMCD, 2006, Volume: 16, Issue:2

    Topics: Adult; Aged; Antioxidants; Atherosclerosis; Cytokines; Dietary Supplements; Drug Therapy, Combinatio

2006
Heart positive: design of a randomized controlled clinical trial of intensive lifestyle intervention, niacin and fenofibrate for HIV lipodystrophy/dyslipidemia.
    Contemporary clinical trials, 2006, Volume: 27, Issue:6

    Topics: Adult; Antiretroviral Therapy, Highly Active; Combined Modality Therapy; Diet, Fat-Restricted; Exerc

2006
[Efficacy and safety of extended-release niacin alone or with atorvastatin for lipid profile modification].
    Zhonghua yi xue za zhi, 2006, Sep-12, Volume: 86, Issue:34

    Topics: Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Coron

2006
Treatment of hyperlipidaemia and progression of atherosclerosis.
    Lancet (London, England), 1983, Nov-19, Volume: 2, Issue:8360

    Topics: Adult; Arteriosclerosis; Colestipol; Double-Blind Method; Female; Humans; Hyperlipidemias; Middle Ag

1983
The prevalence of side effects with regular and sustained-release nicotinic acid.
    The American journal of medicine, 1995, Volume: 99, Issue:4

    Topics: Adult; Aged; Aged, 80 and over; Anticholesteremic Agents; Delayed-Action Preparations; Female; Human

1995
Complementary effects of pravastatin and nicotinic acid in the treatment of combined hyperlipidaemia in diabetic and non-diabetic patients.
    Journal of cardiovascular risk, 1994, Volume: 1, Issue:3

    Topics: Adult; Aged; Blood Glucose; Cholesterol; Diabetes Mellitus, Type 2; Dose-Response Relationship, Drug

1994
Effects of nicotinic acid and lovastatin in renal transplant patients: a prospective, randomized, open-labeled crossover trial.
    American journal of kidney diseases : the official journal of the National Kidney Foundation, 1995, Volume: 25, Issue:4

    Topics: Adult; Anticholesteremic Agents; Blood Glucose; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cro

1995
Nicotinic acid decreases serum thyroid hormone levels while maintaining a euthyroid state.
    Mayo Clinic proceedings, 1995, Volume: 70, Issue:6

    Topics: Adult; Female; Humans; Hyperlipidemias; Liver; Liver Function Tests; Male; Middle Aged; Niacin; Thyr

1995
The effect of nicotinic acid and acipimox on lipoprotein(a) concentration and turnover.
    Atherosclerosis, 1993, Volume: 101, Issue:1

    Topics: Adult; Aged; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Female; Humans; Hyperlipidemias; Hypol

1993
Four years' treatment efficacy of patients with severe hyperlipidemia. Lipid lowering drugs versus LDL-apheresis.
    The International journal of artificial organs, 1995, Volume: 18, Issue:12

    Topics: Adolescent; Adult; Anticholesteremic Agents; Blood Component Removal; Cholesterol, HDL; Cholesterol,

1995
Comparison of pravastatin with crystalline nicotinic acid monotherapy in treatment of combined hyperlipidemia.
    The American journal of cardiology, 1997, May-01, Volume: 79, Issue:9

    Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cross-Over S

1997
Moderate dose, three-drug therapy with niacin, lovastatin, and colestipol to reduce low-density lipoprotein cholesterol <100 mg/dl in patients with hyperlipidemia and coronary artery disease.
    The American journal of cardiology, 1997, Jul-15, Volume: 80, Issue:2

    Topics: Cholesterol, LDL; Colestipol; Cross-Over Studies; Delayed-Action Preparations; Drug Therapy, Combina

1997
Effect of gemfibrozil +/- niacin +/- cholestyramine on endothelial function in patients with serum low-density lipoprotein cholesterol levels <160 mg/dl and high-density lipoprotein cholesterol levels <40 mg/dl.
    The American journal of cardiology, 1997, Oct-01, Volume: 80, Issue:7

    Topics: Aged; Brachial Artery; Cholestyramine Resin; Coronary Disease; Double-Blind Method; Drug Therapy, Co

1997
A randomized trial of the effects of atorvastatin and niacin in patients with combined hyperlipidemia or isolated hypertriglyceridemia. Collaborative Atorvastatin Study Group.
    The American journal of medicine, 1998, Volume: 104, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Atorvastatin; Cholesterol; Female; Heptanoic Acids; Humans; H

1998
Efficacy and safety of one-year treatment with slow-release nicotinic acid. Monitoring of drug concentration in serum.
    International journal of clinical pharmacology and therapeutics, 1998, Volume: 36, Issue:6

    Topics: Adult; Alanine Transaminase; Alkaline Phosphatase; Aspartate Aminotransferases; Biomarkers; Delayed-

1998
Equivalent efficacy of a time-release form of niacin (Niaspan) given once-a-night versus plain niacin in the management of hyperlipidemia.
    Metabolism: clinical and experimental, 1998, Volume: 47, Issue:9

    Topics: Double-Blind Method; Drug Administration Schedule; Female; Humans; Hyperlipidemias; Male; Middle Age

1998
Multiple-dose efficacy and safety of an extended-release form of niacin in the management of hyperlipidemia.
    The American journal of cardiology, 2000, May-01, Volume: 85, Issue:9

    Topics: Adult; Aged; Apolipoproteins B; Cholesterol, LDL; Double-Blind Method; Female; Humans; Hyperlipidemi

2000
Common hepatic lipase gene promoter variant determines clinical response to intensive lipid-lowering treatment.
    Circulation, 2001, Feb-13, Volume: 103, Issue:6

    Topics: Analysis of Variance; Cholesterol, HDL; Colestipol; Coronary Angiography; Coronary Disease; Drug The

2001
Etofibrate but not controlled-release niacin decreases LDL cholesterol and lipoprotein (a) in type IIb dyslipidemic subjects.
    Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologicas, 2001, Volume: 34, Issue:2

    Topics: Analysis of Variance; Cholesterol, HDL; Cholesterol, LDL; Cholesterol, VLDL; Clofibric Acid; Double-

2001
Effect of niacin and atorvastatin on lipoprotein subclasses in patients with atherogenic dyslipidemia.
    The American journal of cardiology, 2001, Aug-01, Volume: 88, Issue:3

    Topics: Anticholesteremic Agents; Atorvastatin; Cholesterol, HDL; Female; Heptanoic Acids; Humans; Hyperlipi

2001
Effect of very-low-dose niacin on high-density lipoprotein in patients undergoing long-term statin therapy.
    American heart journal, 2002, Volume: 143, Issue:3

    Topics: Adult; Aged; Analysis of Variance; Coronary Disease; Drug Therapy, Combination; Female; Humans; Hype

2002
Long-term safety and efficacy of a once-daily niacin/lovastatin formulation for patients with dyslipidemia.
    The American journal of cardiology, 2002, Mar-15, Volume: 89, Issue:6

    Topics: Adult; Aged; Aged, 80 and over; C-Reactive Protein; Cholesterol, HDL; Cholesterol, LDL; Delayed-Acti

2002
Cholesterol-lowering drugs as cardioprotective agents.
    The American journal of cardiology, 1992, Dec-21, Volume: 70, Issue:21

    Topics: Anticholesteremic Agents; Cholestyramine Resin; Coronary Disease; Humans; Hydroxymethylglutaryl-CoA

1992
A clinical trial of oat bran and niacin in the treatment of hyperlipidemia.
    The Journal of family practice, 1992, Volume: 34, Issue:3

    Topics: Adult; Aged; Delayed-Action Preparations; Drug Therapy, Combination; Edible Grain; Female; Humans; H

1992
A comparison of acipimox and nicotinic acid in type 2b hyperlipidaemia.
    British journal of clinical pharmacology, 1992, Volume: 33, Issue:4

    Topics: Adult; Aged; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Lipids; Male; Middle Aged; Niaci

1992
The effect of aspirin on niacin-induced cutaneous reactions.
    The Journal of family practice, 1992, Volume: 34, Issue:2

    Topics: Adult; Aspirin; Double-Blind Method; Drug Therapy, Combination; Female; Flushing; Humans; Hyperlipid

1992
[Angiographic regression of coronary atheromatosis].
    Lakartidningen, 1991, Apr-10, Volume: 88, Issue:15

    Topics: Angiography; Anticholesteremic Agents; Coronary Angiography; Coronary Artery Disease; Drug Therapy,

1991
Contrasting effects of unmodified and time-release forms of niacin on lipoproteins in hyperlipidemic subjects: clues to mechanism of action of niacin.
    Metabolism: clinical and experimental, 1985, Volume: 34, Issue:7

    Topics: Adult; Apolipoprotein A-I; Apolipoprotein A-II; Apolipoproteins A; Cholesterol, HDL; Cholesterol, LD

1985

Other Studies

135 other studies available for niacin and Hyperlipemia

ArticleYear
Molecular identification of high and low affinity receptors for nicotinic acid.
    The Journal of biological chemistry, 2003, Mar-14, Volume: 278, Issue:11

    Topics: Amino Acid Sequence; Animals; Cell Membrane; CHO Cells; Cricetinae; Databases as Topic; DNA, Complem

2003
Reducing CV risk in diabetes: An ADA update.
    The Journal of family practice, 2017, Volume: 66, Issue:5

    Topics: Antihypertensive Agents; Aspirin; Benzhydryl Compounds; Cardiovascular Diseases; Contraindications;

2017
Safety assessment of niacin in the US Food and Drug Administration's mini-sentinel system.
    Pharmacoepidemiology and drug safety, 2018, Volume: 27, Issue:1

    Topics: Adult; Adverse Drug Reaction Reporting Systems; Aged; Aged, 80 and over; Cholesterol, HDL; Delayed-A

2018
Hydroxytyrosol nicotinate, a new multifunctional hypolipidemic and hypoglycemic agent.
    Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie, 2018, Volume: 99

    Topics: Animals; Antioxidants; Blood Glucose; Diabetes Mellitus, Experimental; Diabetes Mellitus, Type 2; Hy

2018
Evolution of Ellipsoid Zone Abnormalities on Optical Coherence Tomography Associated With Niacin Maculopathy.
    JAMA ophthalmology, 2019, Jul-01, Volume: 137, Issue:7

    Topics: Fluorescein Angiography; Humans; Hyperlipidemias; Macular Edema; Male; Middle Aged; Niacin; Tomograp

2019
Hyperlipidaemia and cardiovascular disease: the quantity does not turn into quality!
    Current opinion in lipidology, 2013, Volume: 24, Issue:4

    Topics: Amides; Cardiovascular Diseases; Drug Therapy, Combination; Esters; Humans; Hyperlipidemias; Niacin;

2013
[Relationship of ox-LDL/LOX-1 and vascular endothelial dysfunction of diet-induced obese immature rats and nicotinic acid's intervention outcomes].
    Zhonghua yi xue za zhi, 2013, Nov-12, Volume: 93, Issue:42

    Topics: Animals; Endothelium, Vascular; Hyperlipidemias; Intercellular Adhesion Molecule-1; Lipoproteins, LD

2013
Drugs for lipids.
    Treatment guidelines from the Medical Letter, 2014, Volume: 12, Issue:137

    Topics: Animals; Azetidines; Cholesterol; Drug Interactions; Drug Therapy, Combination; Ezetimibe; Fish Oils

2014
Prolonged niacin treatment leads to increased adipose tissue PUFA synthesis and anti-inflammatory lipid and oxylipin plasma profile.
    Journal of lipid research, 2014, Volume: 55, Issue:12

    Topics: Algorithms; Animals; Anti-Inflammatory Agents, Non-Steroidal; Apolipoprotein E3; Arachidonic Acid; B

2014
Beyond statins: assessing the alternatives. Some people can't tolerate statins, and others need additional medications to achieve healthy cholesterol levels.
    Harvard heart letter : from Harvard Medical School, 2014, Volume: 25, Issue:3

    Topics: Anticholesteremic Agents; Azetidines; Bezafibrate; Cholesterol; Dietary Supplements; Exercise; Ezeti

2014
The use of a hydrogel matrix for controlled delivery of niacin to the gastrointestinal tract for treatment of hyperlipidemia.
    Physiological research, 2015, Volume: 64, Issue:Suppl 1

    Topics: Cross-Linking Reagents; Delayed-Action Preparations; Drug Carriers; Drug Delivery Systems; Gastroint

2015
Trends in the Use of Nonstatin Lipid-Lowering Therapy Among Patients With Coronary Heart Disease: A Retrospective Cohort Study in the Medicare Population 2007 to 2011.
    Journal of the American College of Cardiology, 2015, Oct-27, Volume: 66, Issue:17

    Topics: Adult; Anticholesteremic Agents; Coronary Disease; Drug Utilization; Ezetimibe; Humans; Hyperlipidem

2015
Potentially Reversible Effect of Niacin Therapy on Edema From Retinal Vein Occlusion.
    JAMA ophthalmology, 2016, 07-01, Volume: 134, Issue:7

    Topics: Administration, Oral; Humans; Hyperlipidemias; Hypertension; Macular Edema; Male; Middle Aged; Niaci

2016
Combined effects of niacin and chromium treatment on vascular endothelial dysfunction in hyperlipidemic rats.
    Molecular biology reports, 2009, Volume: 36, Issue:6

    Topics: Animals; Chromium; Down-Regulation; Drug Therapy, Combination; Endothelium, Vascular; Hyperlipidemia

2009
Should we treat all primary prevention patients with statins?
    Current atherosclerosis reports, 2009, Volume: 11, Issue:1

    Topics: Azetidines; Bile Acids and Salts; Cardiovascular Diseases; Cholesterol; Drug Therapy, Combination; E

2009
Lipid disorders.
    JAAPA : official journal of the American Academy of Physician Assistants, 2009, Volume: 22, Issue:11

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Clofibric Acid; Coronary D

2009
LDL = 5: Virtues and dangers of multidrug therapy of low-density lipoprotein cholesterol.
    Preventive cardiology, 2010,Spring, Volume: 13, Issue:2

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, LDL; Drug Therapy, Combination; Ezetimibe; Fenofi

2010
Hyperlipidaemia and cardiovascular disease: low HDL-cholesterol as a therapeutic target in statin-treated patients: a role for nicotinic acid (niacin)?
    Current opinion in lipidology, 2010, Volume: 21, Issue:2

    Topics: Cardiovascular Diseases; Cholesterol, HDL; Drug Interactions; Humans; Hydroxymethylglutaryl-CoA Redu

2010
Therapy and clinical trials: HDL-cholesterol and niacin therapy--past, present, and future.
    Current opinion in lipidology, 2010, Volume: 21, Issue:2

    Topics: Cholesterol, HDL; Cholesterol, LDL; Clinical Trials as Topic; Humans; Hydroxymethylglutaryl-CoA Redu

2010
What does the future hold for niacin as a treatment for hyperlipidaemia and cardiovascular disease?
    Journal of cardiovascular medicine (Hagerstown, Md.), 2010, Volume: 11, Issue:11

    Topics: Biomarkers; Cardiovascular Diseases; Carotid Artery Diseases; Cholesterol, HDL; Cholesterol, LDL; Dr

2010
Niacin, fenofibrates increase benefits for statin users. These HDL- raising, triglyceride-lowering drugs beat out the use of additional LDL-lowering drugs.
    DukeMedicine healthnews, 2010, Volume: 16, Issue:8

    Topics: Carotid Artery Diseases; Cholesterol, HDL; Female; Fenofibrate; Humans; Hyperlipidemias; Hypolipidem

2010
Analgesic benefit of niacin for shrapnel wound pain in war veteran.
    Military medicine, 2010, Volume: 175, Issue:11

    Topics: Aged, 80 and over; Analgesia; Blast Injuries; Cicatrix, Hypertrophic; Humans; Hyperlipidemias; Hypol

2010
Combined effects of niacin and chromium treatment on heart of hyperlipidemic rats.
    Human & experimental toxicology, 2011, Volume: 30, Issue:10

    Topics: Animals; Aryldialkylphosphatase; Chromium; Diet, Atherogenic; Female; gamma-Glutamyltransferase; Glu

2011
Synthesis, characterization and in vitro hydrolysis of a gemfibrozil-nicotinic acid codrug for improvement of lipid profile.
    European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences, 2011, Jun-14, Volume: 43, Issue:3

    Topics: Chromatography, High Pressure Liquid; Esters; Gemfibrozil; Half-Life; Humans; Hydrogen-Ion Concentra

2011
Combining niacin with statins: does it help heart health?
    The Johns Hopkins medical letter health after 50, 2011, Volume: 23, Issue:10

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Drug Interactions; Drug Therapy, Combi

2011
I am among the minority of people who have experienced serious side effects from using a statin. Along with healthy lifestyle choices, are there any other non-statin medications that can help?
    Heart advisor, 2010, Volume: 13, Issue:11

    Topics: Anticholesteremic Agents; Health Behavior; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; H

2010
Niacin seems OK for people with diabetes.
    Health news (Waltham, Mass.), 2002, Volume: 8, Issue:10

    Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Niacin

2002
The rationale for combination therapy.
    The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combin

2002
Combination therapy for elevated low-density lipoprotein cholesterol: the key to coronary artery disease risk reduction.
    The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B

    Topics: Anticholesteremic Agents; Cholesterol, LDL; Coronary Disease; Drug Therapy, Combination; Humans; Hyd

2002
Existing and investigational combination drug therapy for high-density lipoprotein cholesterol.
    The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Coronary Disease; Drug Therapy, Combination; Estrogens;

2002
Use of combination therapy for dyslipidemia: a lipid clinic approach.
    The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B

    Topics: Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy, Combination;

2002
Combination therapy for dyslipidemia: safety and regulatory considerations.
    The American journal of cardiology, 2002, Nov-20, Volume: 90, Issue:10B

    Topics: Algorithms; Anticholesteremic Agents; Azetidines; Cholesterol, HDL; Cholesterol, LDL; Drug Therapy,

2002
Targeting cardiovascular risk associated with both low density and high density lipoproteins using statin-niacin combination therapy.
    Journal of cardiovascular risk, 2002, Volume: 9, Issue:6

    Topics: Anticholesteremic Agents; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coronary Disease; Drug

2002
The use of niacin in diabetes mellitus.
    Archives of internal medicine, 2003, Feb-10, Volume: 163, Issue:3

    Topics: Blood Glucose; Diabetes Mellitus, Type 2; Glycated Hemoglobin; Humans; Hyperlipidemias; Hypolipidemi

2003
Three new drugs for hyperlipidemia.
    The Medical letter on drugs and therapeutics, 2003, Mar-03, Volume: 45, Issue:1151

    Topics: Azetidines; Delayed-Action Preparations; Dose-Response Relationship, Drug; Drug Combinations; Ezetim

2003
Niacin for dyslipidemia: considerations in product selection.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, May-15, Volume: 60, Issue:10

    Topics: Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Patient Compliance; Practice Guidelines as To

2003
Three new drugs for hyperlipidemia.
    Connecticut medicine, 2003, Volume: 67, Issue:5

    Topics: Azetidines; Clinical Trials as Topic; Delayed-Action Preparations; Dose-Response Relationship, Drug;

2003
Effectiveness of aggressive management of dyslipidemia in a collaborative-care practice model.
    The American journal of cardiology, 2003, Jun-15, Volume: 91, Issue:12

    Topics: Adult; Aged; Aged, 80 and over; Biomarkers; Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Coop

2003
Niacin in the treatment of dyslipidemia: insight from Adult Treatment Panel III. Introduction.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Jul-01, Volume: 60, Issue:13 Suppl 2

    Topics: Adult; Aged; Cardiovascular Diseases; Female; Humans; Hyperlipidemias; Male; Middle Aged; Niacin

2003
Overview of niacin formulations: differences in pharmacokinetics, efficacy, and safety.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Jul-01, Volume: 60, Issue:13 Suppl 2

    Topics: Administration, Oral; Chemistry, Pharmaceutical; Clinical Trials as Topic; Delayed-Action Preparatio

2003
Advances in the understanding and management of dyslipidemia: using niacin-based therapies.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Jul-01, Volume: 60, Issue:13 Suppl 2

    Topics: Chemistry, Pharmaceutical; Cholesterol, HDL; Coronary Artery Disease; Delayed-Action Preparations; D

2003
Niacin and the National Cholesterol Education Program Adult Treatment Panel III Guidelines: case studies.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2003, Jul-01, Volume: 60, Issue:13 Suppl 2

    Topics: Aspirin; Atenolol; Blood Chemical Analysis; Coronary Disease; Female; Humans; Hyperlipidemias; Hyper

2003
Oral nicotinic acid for hyperlipemia with emphasis on side effects.
    The American journal of cardiology, 1958, Volume: 2, Issue:4

    Topics: Humans; Hyperlipidemias; Lipids; Niacin; Nicotinic Acids

1958
Some observations on the relationships between atherosclerosis, hyperlipemia, and D-thyroxine.
    American heart journal, 1962, Volume: 64

    Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Dextrothyroxine; Estrogens; Humans; Hyperlipidemias;

1962
Nicotinic acid levels as an index of aluminum nicotinate activity in the treatment of hyperlipemia.
    Journal of the American Geriatrics Society, 1962, Volume: 10

    Topics: Aluminum; Hyperlipidemias; Niacin; Nicotinic Acids

1962
Aluminum nicotinate in the treatment of hypercholesteremia, hyperlipemia, and other elevated lipid levels.
    Current therapeutic research, clinical and experimental, 1962, Volume: 4

    Topics: Aluminum; Aluminum Compounds; Hypercholesterolemia; Hyperlipidemias; Lipids; Niacin; Nicotinic Acids

1962
Treatment of "idiopathic" hyperlipemia.
    Metabolism: clinical and experimental, 1962, Volume: 11

    Topics: Hyperlipidemias; Lipids; Niacin; Nicotinic Acids; Tolbutamide

1962
[Effect of Lipokapsul on the serum lipids in arteriosclerosis (with reference to different diet forms)].
    Die Medizinische Welt, 1962, Sep-01, Volume: 35

    Topics: Arteriosclerosis; Coronary Disease; Diet; Diet Therapy; Fatty Acids; Fatty Acids, Essential; Humans;

1962
EFFECT OF NICOTINIC ACID ON ABNORMAL SERUM LIPIDS.
    British medical journal, 1964, Jan-18, Volume: 1, Issue:5376

    Topics: Child; Cholesterol; Geriatrics; Hypercholesterolemia; Hyperlipidemias; Lipid Metabolism; Lipids; Lip

1964
[FAMILIAL XANTHOMATOUS HYPERCHOLESTEREMIA].
    Coeur et medecine interne, 1963, Volume: 58

    Topics: Adrenocorticotropic Hormone; Cortisone; Diagnosis, Differential; Diet; Diet Therapy; Dietary Fats; E

1963
[STUDIES ON THE TREATMENT OF ENDOGENOUS HYPERLIPOPROTEINEMIA WITH BETA-PYRIDYL-CARBINOL].
    Klinische Wochenschrift, 1963, Nov-15, Volume: 41

    Topics: Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemias; Lipoproteins; Methanol; Niacin

1963
[THE SIGNIFICANCE OF INSUFFICIENT CLEARANCE IN ATHEROGENESIS].
    Munchener medizinische Wochenschrift (1950), 1963, Dec-13, Volume: 105

    Topics: Arteriosclerosis; Atherosclerosis; Dietary Fats; Glycerides; Heparin; Heparinoids; Hypercholesterole

1963
[PROLONGED TREATMENT WITH LARGE DOSES OF NICOTINIC ACID IN CORONARY ARTERIOSCLEROSIS].
    Medicina interna, 1964, Volume: 16

    Topics: Coronary Artery Disease; Coronary Disease; Humans; Hyperlipidemias; Niacin; Nicotinic Acids

1964
[STUDIES ON THE INFLUENCING OF FAT CLEARANCE IN VIVO].
    Deutsches medizinisches Journal, 1964, Feb-05, Volume: 15

    Topics: Adenosine Triphosphate; Arteriosclerosis; Dietary Fats; Heparin; Hyperlipidemias; Hypertension; Iodi

1964
[ON CHOLESTEROL MOBILIZATION IN THE TREATMENT OF XANTHOMA AND ATHEROSCLEROSIS].
    Arzneimittel-Forschung, 1963, Volume: 13

    Topics: Arteriosclerosis; Atherosclerosis; Cholesterol; Drug Therapy; Heparin; Humans; Hypercholesterolemia;

1963
[COMPLAMINE TREATMENT OF PATIENTS WITH INCREASED SERUM CHOLESTEROL VALUES].
    Svenska lakartidningen, 1964, Sep-09, Volume: 61

    Topics: Cholesterol; Coronary Disease; Humans; Hypercholesterolemia; Hyperlipidemias; Niacin; Nicotinic Acid

1964
[BLOOD LIPIDS IN ATHEROSCLEROSIS AND THE ACTION OF SOME AGENTS MODIFYING LIPEMIA].
    Acta gastro-enterologica Belgica, 1964, Volume: 27

    Topics: Androsterone; Anticholesteremic Agents; Arteriosclerosis; Atherosclerosis; Butyrates; Cholesterol; D

1964
[RESEARCH ON THE INFLUENCE OF NICOTINIC ACID ON SERUM LIPID FRACTIONS].
    Il Progresso medico, 1964, Nov-15, Volume: 20

    Topics: Drug Therapy; Humans; Hyperlipidemias; Lipids; Niacin; Nicotinic Acids; Research

1964
[NEW POSSIBILITIES IN THE DIAGNOSIS AND MEASURES FOR DRUG CONTROL OF DEGENERATIVE VASCULAR DISEASES].
    Die Medizinische Welt, 1964, Oct-17, Volume: 42

    Topics: Anticholesteremic Agents; Arteriosclerosis; Blood Chemical Analysis; Cardiovascular Diseases; Corona

1964
[STUDIES ON THE CONTROLLABILITY OF FAT-CLEARANCE INSUFFICIENCY].
    Medizinische Klinik, 1964, Sep-11, Volume: 59

    Topics: Humans; Hyperlipidemias; Lipid Metabolism; Niacin; Nicotinic Acids; Vascular Diseases

1964
Once-daily niacin extended release/lovastatin combination tablet has more favorable effects on lipoprotein particle size and subclass distribution than atorvastatin and simvastatin.
    Preventive cardiology, 2003,Fall, Volume: 6, Issue:4

    Topics: Aged; Atorvastatin; Cholesterol, HDL; Cholesterol, LDL; Drug Combinations; Female; Heptanoic Acids;

2003
Effect of baseline levels on response of high-density lipoprotein cholesterol to hypolipidemic treatment.
    The American journal of cardiology, 2003, Dec-01, Volume: 92, Issue:11

    Topics: Cholesterol, HDL; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Linear Models; Male; Middle

2003
[New drug against lipid disorders. HDL level rises 30%].
    MMW Fortschritte der Medizin, 2003, Sep-25, Volume: 145, Issue:39

    Topics: Cholesterol, HDL; Coronary Disease; Female; Humans; Hyperlipidemias; Hypolipidemic Agents; Life Styl

2003
Varying cost and free nicotinic acid content in over-the-counter niacin preparations for dyslipidemia.
    Annals of internal medicine, 2003, Dec-16, Volume: 139, Issue:12

    Topics: Chromatography, High Pressure Liquid; Dosage Forms; Fees, Pharmaceutical; Humans; Hyperlipidemias; N

2003
[HDL cholesterol as protective factor. Deficiency threatens the diabetic heart].
    MMW Fortschritte der Medizin, 2003, Nov-27, Volume: 145, Issue:48

    Topics: Cholesterol, HDL; Clinical Trials as Topic; Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Hypo

2003
Purported benefits of inositol niacinate.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 2004, Feb-01, Volume: 61, Issue:3

    Topics: Administration, Oral; Anticholesteremic Agents; Humans; Hyperlipidemias; Inositol; Lipoproteins, VLD

2004
Statins as the cornerstone of drug therapy for dyslipidemia: monotherapy and combination therapy options.
    American heart journal, 2004, Volume: 148, Issue:1 Suppl

    Topics: Alanine Transaminase; Aspartate Aminotransferases; Cholesterol, LDL; Clinical Trials as Topic; Creat

2004
Beneficial effects of combined treatment with niacin and chromium on the liver of hyperlipemic rats.
    Biological trace element research, 2004, Volume: 101, Issue:3

    Topics: Animals; Cholesterol; Chromium; Dietary Fats; Female; Hyperlipidemias; Hypolipidemic Agents; Lipids;

2004
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
    Drug safety, 2005, Volume: 28, Issue:3

    Topics: Aged; Ambulatory Care; Aryl Hydrocarbon Hydroxylases; Atorvastatin; Comorbidity; Cross-Sectional Stu

2005
Effects of a combination of niacin and chromium(III)-chloride on the skin and lungs of hyperlipemic rats.
    Biological trace element research, 2005, Volume: 103, Issue:3

    Topics: Animals; Chlorides; Chromium Compounds; Diet; Female; Glutathione; Hyperlipidemias; Lipid Peroxidati

2005
Influence of extended-release nicotinic acid on nonesterified fatty acid flux in the metabolic syndrome with atherogenic dyslipidemia.
    The American journal of cardiology, 2005, Jun-01, Volume: 95, Issue:11

    Topics: Adult; Aged; Blood Glucose; Crystallization; Delayed-Action Preparations; Diabetes Mellitus; Fatty A

2005
Cloricromene effect on the enzyme activities of the tryptophan-nicotinic acid pathway in diabetic/hyperlipidemic rabbits.
    Life sciences, 2006, Jan-18, Volume: 78, Issue:8

    Topics: Animals; Cholesterol, Dietary; Chromonar; Diabetes Mellitus, Experimental; Free Radical Scavengers;

2006
[Innovative therapies in metabolic diseases: ezetimibe (Ezétrol), nicotinic acid (Niaspan), acids omega-3 (Omacor), rimonabant (Acomplia)].
    Revue medicale de Bruxelles, 2005, Volume: 26, Issue:4

    Topics: Anticholesteremic Agents; Azetidines; Ezetimibe; Fatty Acids, Omega-3; Humans; Hyperlipidemias; Hypo

2005
The effect of combined treatment with niacin and chromium (III) chloride on the different tissues of hyperlipemic rats.
    Drug and chemical toxicology, 2006, Volume: 29, Issue:4

    Topics: Animals; Catalase; Chlorides; Cholesterol; Chromium Compounds; Dietary Fats; Disease Models, Animal;

2006
Adipokines and treatment with niacin.
    Metabolism: clinical and experimental, 2006, Volume: 55, Issue:10

    Topics: Adiponectin; Adult; Aged; Cholesterol; Cholesterol, HDL; Cytokines; Delayed-Action Preparations; Fem

2006
The effects of combined treatment with niacin and chromium on the renal tissues of hyperlipidemic rats.
    Molecular and cellular biochemistry, 2007, Volume: 294, Issue:1-2

    Topics: Animals; Chromium; Creatinine; Dietary Fats; Drug Therapy, Combination; Female; Glutathione; Hyperli

2007
Ameliorating effect of coenzyme Q10, riboflavin and niacin in tamoxifen-treated postmenopausal breast cancer patients with special reference to lipids and lipoproteins.
    Clinical biochemistry, 2007, Volume: 40, Issue:9-10

    Topics: Adult; Aged; Breast Neoplasms; Cholesterol, LDL; Cholesterol, VLDL; Coenzymes; Drug Therapy, Combina

2007
Cholesterol efflux and the effect of combined treatment with niacin and chromium on aorta of hyperlipidemic rat.
    Molecular and cellular biochemistry, 2008, Volume: 308, Issue:1-2

    Topics: Adipose Tissue; Animals; Aorta; Cholesterol; Chromium; Drug Synergism; Endothelial Cells; Female; Gl

2008
[Effect of niacin on HDL-induced cholesterol efflux and LXRalpha expression in adipocytes of hypercholesterolemic rabbits].
    Zhonghua xin xue guan bing za zhi, 2007, Volume: 35, Issue:8

    Topics: Adipocytes; Animals; Cholesterol; Disease Models, Animal; DNA-Binding Proteins; Hypercholesterolemia

2007
Assessment of hypolipidaemic activity of three thiazolidin-4-ones in mice given high-fat diet and fructose.
    Chemico-biological interactions, 2008, Feb-15, Volume: 171, Issue:3

    Topics: Administration, Oral; Animals; Blood Glucose; Cholesterol; Diet; Dietary Fats; Disease Models, Anima

2008
[Safety and effectiveness of nicotinic acid in the management of patients with chronic renal disease and hyperlipidemia associated to hyperphosphatemia].
    Nefrologia : publicacion oficial de la Sociedad Espanola Nefrologia, 2008, Volume: 28, Issue:1

    Topics: Chronic Disease; Female; Humans; Hyperlipidemias; Hyperphosphatemia; Hypolipidemic Agents; Kidney Di

2008
[Use of prolonged-release nicotinic acid in patients treated with statins as a secondary prevention and a persistently low HDL-cholesterol level in France].
    Annales de cardiologie et d'angeiologie, 2008, Volume: 57, Issue:2

    Topics: Cholesterol, HDL; Delayed-Action Preparations; Female; France; Humans; Hydroxymethylglutaryl-CoA Red

2008
Abnormalities of lipid metabolism and methods of their correction in patients with glomerulonephritis.
    International urology and nephrology, 1984, Volume: 16, Issue:4

    Topics: Adolescent; Adult; Arteriosclerosis; Clofibrate; Dipyridamole; Female; Glomerulonephritis; Humans; H

1984
Gemfibrozil in combination with other drugs for severe hyperlipidemia. Preliminary study comprising four cases.
    Postgraduate medicine, 1983, Volume: 73, Issue:4

    Topics: Adult; Cholesterol; Cholestyramine Resin; Colestipol; Drug Therapy, Combination; Female; Gemfibrozil

1983
Pharmacologic therapy for the hyperlipidemic patient.
    The American journal of medicine, 1983, May-23, Volume: 74, Issue:5A

    Topics: Bile Acids and Salts; Clofibrate; Dextrothyroxine; Humans; Hyperlipidemias; Hypolipidemic Agents; Ni

1983
Severe hypertriglyceridaemia responding to insulin and nicotinic acid therapy.
    Postgraduate medical journal, 1981, Volume: 57, Issue:670

    Topics: Diabetes Complications; Diabetes Mellitus; Drug Therapy, Combination; Humans; Hypercholesterolemia;

1981
The spontaneously hyperlipidemic old rat as a model for evaluation of hypolipoproteinemic drugs. Effects of nicotinic acid, clofibrate and ethyl 2-(4-dibenzofuranyloxy)-2-methylpropionate on plasma lipoproteins.
    Zeitschrift fur Versuchstierkunde, 1982, Volume: 24, Issue:5-6

    Topics: Aging; Animals; Cholesterol; Clofibrate; Drug Evaluation, Preclinical; Hyperlipidemias; Lipoproteins

1982
Criteria for use of hypolipidemic agents in adults.
    American journal of hospital pharmacy, 1994, Nov-15, Volume: 51, Issue:22

    Topics: Adult; Anticholesteremic Agents; Cholestyramine Resin; Colestipol; Female; Gemfibrozil; Humans; Hydr

1994
Adverse ocular effects associated with niacin therapy.
    The British journal of ophthalmology, 1995, Volume: 79, Issue:1

    Topics: Adult; Aged; Aged, 80 and over; Edema; Eye Diseases; Eyelid Diseases; Female; Humans; Hyperlipidemia

1995
Why aren't we using more niacin?
    Archives of family medicine, 1994, Volume: 3, Issue:4

    Topics: Humans; Hyperlipidemias; Niacin

1994
Effects of nicotinic acid treatment on glyceride formation and lipolysis in adipose tissue of hyperlipidemic patients.
    International journal of clinical & laboratory research, 1993, Volume: 23, Issue:2

    Topics: Adipose Tissue; Adult; Aged; Fatty Acids; Female; Follow-Up Studies; Glucose; Glycerides; Humans; Hy

1993
Effect of a combination of gemfibrozil and niacin on lipid levels.
    Journal of clinical pharmacology, 1996, Volume: 36, Issue:8

    Topics: Diet Therapy; Drug Therapy, Combination; Female; Gemfibrozil; Humans; Hyperlipidemias; Hypolipidemic

1996
Relative effectiveness of niacin and lovastatin for treatment of dyslipidemias in a health maintenance organization.
    The Journal of family practice, 1997, Volume: 44, Issue:5

    Topics: Cholesterol, HDL; Cholesterol, LDL; Cohort Studies; Female; Follow-Up Studies; Health Maintenance Or

1997
[The effect of long-term Enduracin monotherapy on the clinical and biochemical status of patients with ischemic heart disease].
    Terapevticheskii arkhiv, 1997, Volume: 69, Issue:9

    Topics: Adult; Cardiovascular System; Coronary Artery Disease; Delayed-Action Preparations; Digestive System

1997
Safe use of niacin.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, Dec-15, Volume: 54, Issue:24

    Topics: Diabetes Mellitus; Humans; Hyperlipidemias; Niacin

1997
ASHP Therapeutic Position Statement on the safe use of niacin in the management of dyslipidemias. American Society of Health-System Pharmacists.
    American journal of health-system pharmacy : AJHP : official journal of the American Society of Health-System Pharmacists, 1997, Dec-15, Volume: 54, Issue:24

    Topics: Chemical and Drug Induced Liver Injury; Drug Monitoring; Gastrointestinal Diseases; Humans; Hyperlip

1997
The new cholesterol education imperative and some comments on niacin.
    The American journal of cardiology, 1998, Feb-15, Volume: 81, Issue:4

    Topics: Drug Therapy, Combination; Humans; Hyperlipidemias; Lipids; Niacin; Patient Education as Topic

1998
Dental and gingival pain as side effects of niacin therapy.
    Chest, 1998, Volume: 114, Issue:5

    Topics: Aged; Gingiva; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Niacin; Pain; Toothache

1998
The effect of the mode of administration on the hypolipidaemic activity of niacin: continuous gastrointestinal administration of low-dose niacin improves lipid-lowering efficacy in experimentally-induced hyperlipidaemic rats.
    The Journal of pharmacy and pharmacology, 1998, Volume: 50, Issue:11

    Topics: Animals; Aspartate Aminotransferases; Cholesterol; Cholesterol, Dietary; Drug Administration Schedul

1998
A new extended-release niacin (Niaspan): efficacy, tolerability, and safety in hypercholesterolemic patients.
    The American journal of cardiology, 1998, Dec-17, Volume: 82, Issue:12A

    Topics: Cholesterol, LDL; Delayed-Action Preparations; Female; Flushing; Humans; Hyperlipidemias; Hypolipide

1998
[Lipid and non-lipid effects of enduracin in patients with arterial hypertension].
    Terapevticheskii arkhiv, 1999, Volume: 71, Issue:8

    Topics: Blood Flow Velocity; Blood Pressure; Cerebral Arteries; Cerebrovascular Circulation; Female; Humans;

1999
Dietitian intervention improves lipid values and saves medication costs in men with combined hyperlipidemia and a history of niacin noncompliance.
    Journal of the American Dietetic Association, 2000, Volume: 100, Issue:2

    Topics: Adult; Aged; Anticholesteremic Agents; Cholesterol; Cholesterol, HDL; Cholesterol, LDL; Cost-Benefit

2000
Diagnosis, management and prevention of the common dyslipidaemias in South Africa--clinical guideline, 2000. South African Medical Association and Lipid and Atherosclerosis Society of Southern Africa Working Group.
    South African medical journal = Suid-Afrikaanse tydskrif vir geneeskunde, 2000, Volume: 90, Issue:2 Pt 2

    Topics: Cholestyramine Resin; Dose-Response Relationship, Drug; Drug Therapy, Combination; Humans; Hydroxyme

2000
Pharmacodynamic effects of bezafibrate and niacin combination: implications of the mode of administration.
    Journal of pharmaceutical sciences, 2000, Volume: 89, Issue:8

    Topics: Animals; Bezafibrate; Cholesterol; Drug Therapy, Combination; Hyperlipidemias; Hypolipidemic Agents;

2000
Co-administration of equimolar doses of betaine may alleviate the hepatotoxic risk associated with niacin therapy.
    Medical hypotheses, 2000, Volume: 55, Issue:3

    Topics: Animals; Betaine; Homocysteine; Hyperlipidemias; Liver; Niacin; Rats; S-Adenosylmethionine

2000
Safety and effectiveness of Niaspan when added sequentially to a statin for treatment of dyslipidemia.
    The American journal of cardiology, 2001, Feb-15, Volume: 87, Issue:4

    Topics: Adult; Anticholesteremic Agents; Drug Therapy, Combination; Female; Humans; Hyperlipidemias; Male; M

2001
[Indications for the pharmacologic treatment of hyperlipidemias].
    Revista clinica espanola, 2000, Volume: 200, Issue:11

    Topics: Bile Acids and Salts; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; Hyperlipidemias; Hypol

2000
Hyperlipemia: a role in regulating UCP3 gene expression in skeletal muscle during cancer cachexia?
    FEBS letters, 2001, Sep-14, Volume: 505, Issue:2

    Topics: Animals; Blotting, Northern; Cachexia; Carrier Proteins; Fatty Acids, Nonesterified; Gene Expression

2001
Tolerability of statin-fibrate and statin-niacin combination therapy in dyslipidemic patients at high risk for cardiovascular events.
    The American journal of cardiology, 2002, Feb-15, Volume: 89, Issue:4

    Topics: Cardiovascular Diseases; Drug Therapy, Combination; Drug Tolerance; Female; Humans; Hydroxymethylglu

2002
Lipid-lowering drug use and cardiovascular events after myocardial infarction.
    The Annals of pharmacotherapy, 2002, Volume: 36, Issue:5

    Topics: Cholesterol; Clofibrate; Cohort Studies; Coronary Artery Disease; Coronary Disease; Female; Humans;

2002
Enzyme activities along the tryptophan-nicotinic acid pathway in alloxan diabetic rabbits.
    Biochimica et biophysica acta, 2002, May-10, Volume: 1571, Issue:1

    Topics: 3-Hydroxyanthranilate 3,4-Dioxygenase; Animals; Carboxy-Lyases; Cholesterol, Dietary; Diabetes Melli

2002
Relation between arteriographically diagnosed femoral atherosclerosis and serum lipids. Prevalence and treatment in hyperlipidaemic subjects.
    Acta radiologica. Supplementum, 1992, Volume: 378 ( Pt 3)

    Topics: Adult; Aged; Aorta, Abdominal; Aortic Aneurysm; Arteriosclerosis; Drug Therapy, Combination; Femoral

1992
Effects of nicotinic acid treatment on fatty acid composition of plasma lipids and adipose tissue in hyperlipidaemia.
    Scandinavian journal of clinical and laboratory investigation, 1992, Volume: 52, Issue:6

    Topics: Adipose Tissue; Adult; Aged; Fatty Acids; Female; Humans; Hyperlipidemias; Lipids; Male; Middle Aged

1992
Niacin benefits.
    The Western journal of medicine, 1992, Volume: 156, Issue:2

    Topics: Humans; Hyperlipidemias; Niacin

1992
Clarification. Drug therapy for hyperlipidemia: when reducing cardiovascular risk is a priority.
    Postgraduate medicine, 1992, Volume: 91, Issue:8

    Topics: Humans; Hyperlipidemias; Niacin

1992
Hepatotoxicity associated with sustained-release niacin.
    The American journal of medicine, 1992, Volume: 93, Issue:1

    Topics: Aged; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Female; Humans; Hyperlipi

1992
Effect of bezafibrate & nicotinic acid on triton induced hyperlipidemias in CFY rats.
    The Indian journal of medical research, 1991, Volume: 94

    Topics: Animals; Bezafibrate; Cholesterol; Drug Therapy, Combination; Hyperlipidemias; Male; Niacin; Polyeth

1991
Rediscovery of crystalline niacin.
    Mayo Clinic proceedings, 1991, Volume: 66, Issue:1

    Topics: Chemical and Drug Induced Liver Injury; Humans; Hyperlipidemias; Niacin

1991
Niacin-induced hepatitis: a potential side effect with low-dose time-release niacin.
    Mayo Clinic proceedings, 1991, Volume: 66, Issue:1

    Topics: Adult; Chemical and Drug Induced Liver Injury; Delayed-Action Preparations; Female; Humans; Hyperlip

1991
Lactic acidosis associated with high-dose niacin therapy.
    Southern medical journal, 1991, Volume: 84, Issue:4

    Topics: Acidosis, Lactic; Adult; Delayed-Action Preparations; Humans; Hyperlipidemias; Lactates; Male; Niaci

1991
[Antilipemic agents and postprandial lipidemia].
    Klinische Wochenschrift, 1990, Volume: 68 Suppl 22

    Topics: Cholesterol; Chylomicrons; Coronary Artery Disease; Dietary Fats; Diterpenes; Female; Fenofibrate; H

1990
The effects of nicotinic acid treatment on high density lipoprotein particle size subclass levels in hyperlipidaemic subjects.
    Atherosclerosis, 1990, Volume: 83, Issue:2-3

    Topics: Adult; Cholesterol, HDL; Cholesterol, LDL; Coronary Artery Disease; Dose-Response Relationship, Drug

1990
Nicotinic acid in NIDDM.
    JAMA, 1990, Dec-19, Volume: 264, Issue:23

    Topics: Diabetes Mellitus, Type 2; Humans; Hyperlipidemias; Lipids; Niacin

1990
The effect of serum lipid regulation on the development of femoral atherosclerosis in hyperlipidaemia: a non-randomized controlled study.
    Journal of internal medicine, 1990, Volume: 227, Issue:6

    Topics: Adult; Analysis of Variance; Arteriosclerosis; Blood Pressure; Cholesterol, VLDL; Combined Modality

1990
Treating hyperlipidemia, Part III: Drug therapy.
    Geriatrics, 1987, Volume: 42, Issue:8

    Topics: Aged; Enzyme Inhibitors; Gemfibrozil; Heptanoic Acids; Humans; Hypercholesterolemia; Hyperlipidemias

1987
Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
    Atherosclerosis, 1988, Volume: 70, Issue:1-2

    Topics: Animals; Cholesterol, Dietary; Disease Models, Animal; Drug Evaluation, Preclinical; Female; Fenofib

1988
Potential problems with the widespread use of niacin.
    The American journal of medicine, 1988, Volume: 85, Issue:6

    Topics: Adult; Cholesterol; Humans; Hyperlipidemias; Hypolipidemic Agents; Male; Niacin

1988
[Strains and species differences in experimental hyperlipidemia].
    Nihon yakurigaku zasshi. Folia pharmacologica Japonica, 1986, Volume: 87, Issue:3

    Topics: Animals; Clofibrate; Disease Models, Animal; Gemfibrozil; Glycerides; Hyperlipidemias; Hypolipidemic

1986
Medical management of hyperlipidemia and the role of probucol.
    The American journal of cardiology, 1986, Jun-27, Volume: 57, Issue:16

    Topics: Adult; Arteriosclerosis; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Colestipol; Female; Gem

1986
Current pharmacologic treatment of elevated serum cholesterol.
    Circulation, 1987, Volume: 76, Issue:3

    Topics: Adult; Anticholesteremic Agents; Cholesterol; Cholesterol, LDL; Cholestyramine Resin; Clofibrate; Co

1987
Adverse effects of the treatment for hyperlipidemia.
    Cardiology clinics, 1986, Volume: 4, Issue:1

    Topics: Anion Exchange Resins; Anticholesteremic Agents; Bibliographies as Topic; Clofibrate; Diet; Drug The

1986
[Drugs in hyperlipidemia].
    Nederlands tijdschrift voor geneeskunde, 1987, Sep-05, Volume: 131, Issue:36

    Topics: Cholestyramine Resin; Clofibrate; Humans; Hypercholesterolemia; Hyperlipidemias; Hyperlipoproteinemi

1987
[Drug treatment of hyperlipidemia].
    Therapeutische Umschau. Revue therapeutique, 1987, Volume: 44, Issue:8

    Topics: Cholesterol; Coronary Disease; Humans; Hyperlipidemias; Hypolipidemic Agents; Niacin; Risk Factors;

1987
[Changes in lysozyme activity in hyperlipidemia and atherosclerosis in animals].
    Nauchnye doklady vysshei shkoly. Biologicheskie nauki, 1985, Issue:4

    Topics: Adjuvants, Immunologic; Animals; Arteriosclerosis; Enzyme Activation; Hypercholesterolemia; Hyperlip

1985
Xanthomas and hyperlipidemias.
    Journal of the American Academy of Dermatology, 1985, Volume: 13, Issue:1

    Topics: Apoproteins; Arteriosclerosis; Cholestasis; Cholestyramine Resin; Clofibrate; Colestipol; Dextrothyr

1985